Review



human recombinant saa1 protein  (OriGene)


Bioz Verified Symbol OriGene is a verified supplier
Bioz Manufacturer Symbol OriGene manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    OriGene human recombinant saa1 protein
    (A) Cell-cell communication analysis of SAA signaling pathway for the indicated depots and cells. Line colors and widths represent the sending cell and the strength of the signal, respectively. (B) Pseudobulk comparison of differentially expressed genes in epiploic vs. subcutaneous depots, highlighting the indicated signaling pathways. (C) Expression of <t>SAA1</t> mRNA upon stimulation with LPS (10 ng/mL), TNF-α (2.5 ng/mL), IL-1β (10 ng/mL), or IL-6 (10 ng/mL) for 24 h. Data are presented as fold change (FC) over vehicle. Significant (<0.05) p values compared with the vehicle from one-way ANOVA are shown. (D) Relative expression of SAA1 (left) and SAA2 (right) mRNA in adipocytes, ASPCs, adipose-derived endothelial cells (adECs), and THP1-derived macrophages (THP1 M0). Significant (<0.05) p values compared with the cell-type-specific control from one-way ANOVA are shown. (E) Results from ELISA measurements of SAA in conditioned media from human adipocytes incubated without or with LPS for 72 h. Results are displayed as mean, error bars represent standard error of the mean, and statistical significance was calculated using Student’s t test. (F) Analyses of DNA methylation in the indicated cell classes for the promoter and gene body regions of SAA1 and SAA2 , respectively. Chromosomal localization and motifs for NFKB2/RELA/REL and STAT3 are indicated for both genes. (G) SAA1 and SAA2 mRNA expression in adipocytes treated with or without LPS in the presence or absence of different inhibitors described in the main text. Data are presented as FC over vehicle. Significant (<0.05) p values compared with the vehicle from one-way ANOVA are shown. For (C), (D), and (G), data are displayed as geometric mean ± 95% confidence intervals with technical replicates displayed from three independent experiments. ASPC, adipose stromal and progenitor cell.
    Human Recombinant Saa1 Protein, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+saa1/Serum+Amyloid+A+(SAA1)+(NM_000331)+Human+Recombinant+Protein/pmc12989110-39-0-5
    Average 94 stars, based on 1 article reviews
    human recombinant saa1 protein - by Bioz Stars, 2026-11
    94/100 stars

    Images

    1) Product Images from "Cytoarchitectural multi-depot profiling reveals immune-metabolic crosstalk in human colon-associated adipose tissue"

    Article Title: Cytoarchitectural multi-depot profiling reveals immune-metabolic crosstalk in human colon-associated adipose tissue

    Journal: Cell metabolism

    doi: 10.1016/j.cmet.2025.12.008

    (A) Cell-cell communication analysis of SAA signaling pathway for the indicated depots and cells. Line colors and widths represent the sending cell and the strength of the signal, respectively. (B) Pseudobulk comparison of differentially expressed genes in epiploic vs. subcutaneous depots, highlighting the indicated signaling pathways. (C) Expression of SAA1 mRNA upon stimulation with LPS (10 ng/mL), TNF-α (2.5 ng/mL), IL-1β (10 ng/mL), or IL-6 (10 ng/mL) for 24 h. Data are presented as fold change (FC) over vehicle. Significant (<0.05) p values compared with the vehicle from one-way ANOVA are shown. (D) Relative expression of SAA1 (left) and SAA2 (right) mRNA in adipocytes, ASPCs, adipose-derived endothelial cells (adECs), and THP1-derived macrophages (THP1 M0). Significant (<0.05) p values compared with the cell-type-specific control from one-way ANOVA are shown. (E) Results from ELISA measurements of SAA in conditioned media from human adipocytes incubated without or with LPS for 72 h. Results are displayed as mean, error bars represent standard error of the mean, and statistical significance was calculated using Student’s t test. (F) Analyses of DNA methylation in the indicated cell classes for the promoter and gene body regions of SAA1 and SAA2 , respectively. Chromosomal localization and motifs for NFKB2/RELA/REL and STAT3 are indicated for both genes. (G) SAA1 and SAA2 mRNA expression in adipocytes treated with or without LPS in the presence or absence of different inhibitors described in the main text. Data are presented as FC over vehicle. Significant (<0.05) p values compared with the vehicle from one-way ANOVA are shown. For (C), (D), and (G), data are displayed as geometric mean ± 95% confidence intervals with technical replicates displayed from three independent experiments. ASPC, adipose stromal and progenitor cell.
    Figure Legend Snippet: (A) Cell-cell communication analysis of SAA signaling pathway for the indicated depots and cells. Line colors and widths represent the sending cell and the strength of the signal, respectively. (B) Pseudobulk comparison of differentially expressed genes in epiploic vs. subcutaneous depots, highlighting the indicated signaling pathways. (C) Expression of SAA1 mRNA upon stimulation with LPS (10 ng/mL), TNF-α (2.5 ng/mL), IL-1β (10 ng/mL), or IL-6 (10 ng/mL) for 24 h. Data are presented as fold change (FC) over vehicle. Significant (<0.05) p values compared with the vehicle from one-way ANOVA are shown. (D) Relative expression of SAA1 (left) and SAA2 (right) mRNA in adipocytes, ASPCs, adipose-derived endothelial cells (adECs), and THP1-derived macrophages (THP1 M0). Significant (<0.05) p values compared with the cell-type-specific control from one-way ANOVA are shown. (E) Results from ELISA measurements of SAA in conditioned media from human adipocytes incubated without or with LPS for 72 h. Results are displayed as mean, error bars represent standard error of the mean, and statistical significance was calculated using Student’s t test. (F) Analyses of DNA methylation in the indicated cell classes for the promoter and gene body regions of SAA1 and SAA2 , respectively. Chromosomal localization and motifs for NFKB2/RELA/REL and STAT3 are indicated for both genes. (G) SAA1 and SAA2 mRNA expression in adipocytes treated with or without LPS in the presence or absence of different inhibitors described in the main text. Data are presented as FC over vehicle. Significant (<0.05) p values compared with the vehicle from one-way ANOVA are shown. For (C), (D), and (G), data are displayed as geometric mean ± 95% confidence intervals with technical replicates displayed from three independent experiments. ASPC, adipose stromal and progenitor cell.

    Techniques Used: Comparison, Protein-Protein interactions, Expressing, Derivative Assay, Control, Enzyme-linked Immunosorbent Assay, Incubation, DNA Methylation Assay

    (A) Top Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways based on differentially expressed genes from comparisons of SAA1- or LPS-treated vs. control-treated adipose-derived stromal-vascular cells. (B) Network view of the six common SAA1- and LPS-regulated pathways showing shared and treatment-specific genes. (C) Expression scores for SAA1- (left) and LPS-responsive (right) genes following a 6-h incubation with either ligand in stromal-vascular cells from subcutaneous human WAT. Results are displayed on the uniform manifold approximation and projection panel from and violin plots for each indicated cell class. Note that adipocytes and mesothelial cells were removed as these are not present in the stromal-vascular fraction from the subcutaneous depot. (D) Representative immunostaining of epiploic adipose tissue using antibodies directed against markers for Adipo SAA (CES1) and macrophages (CD68). Hoechst33342 was used as the counterstain for nuclei. Scale bar, 100 μm. ASPC, adipose stromal and progenitor cell; NES, normalized enrichment score.
    Figure Legend Snippet: (A) Top Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways based on differentially expressed genes from comparisons of SAA1- or LPS-treated vs. control-treated adipose-derived stromal-vascular cells. (B) Network view of the six common SAA1- and LPS-regulated pathways showing shared and treatment-specific genes. (C) Expression scores for SAA1- (left) and LPS-responsive (right) genes following a 6-h incubation with either ligand in stromal-vascular cells from subcutaneous human WAT. Results are displayed on the uniform manifold approximation and projection panel from and violin plots for each indicated cell class. Note that adipocytes and mesothelial cells were removed as these are not present in the stromal-vascular fraction from the subcutaneous depot. (D) Representative immunostaining of epiploic adipose tissue using antibodies directed against markers for Adipo SAA (CES1) and macrophages (CD68). Hoechst33342 was used as the counterstain for nuclei. Scale bar, 100 μm. ASPC, adipose stromal and progenitor cell; NES, normalized enrichment score.

    Techniques Used: Control, Derivative Assay, Expressing, Incubation, Immunostaining

    Related Articles

    other:

    Article Title: Serum amyloid A is a soluble pattern recognition receptor that drives type 2 immunity.
    Article Snippet: 1Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.. 2Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.. 3Institute of Molecular Biosciences, BioTechMed Graz, University of Graz, Graz, Austria.

    Produced:

    Article Title: Bacterial lipoproteins constitute the TLR2-stimulating activity of Serum Amyloid A
    Article Snippet: .. Human SAA1 from Origene produced in HEK cells (hSAA1) or ovalbumin (Ova) was unexposed or exposed to Pam3CSK4 (Pam) overnight (control), and some of the preparation was subjected to concentration of proteins >3 kDa using concentrated using Amicon Ultra centrifugal concentrators (filtered). ..

    Control:

    Article Title: Bacterial lipoproteins constitute the TLR2-stimulating activity of Serum Amyloid A
    Article Snippet: .. Human SAA1 from Origene produced in HEK cells (hSAA1) or ovalbumin (Ova) was unexposed or exposed to Pam3CSK4 (Pam) overnight (control), and some of the preparation was subjected to concentration of proteins >3 kDa using concentrated using Amicon Ultra centrifugal concentrators (filtered). ..

    Concentration Assay:

    Article Title: Bacterial lipoproteins constitute the TLR2-stimulating activity of Serum Amyloid A
    Article Snippet: .. Human SAA1 from Origene produced in HEK cells (hSAA1) or ovalbumin (Ova) was unexposed or exposed to Pam3CSK4 (Pam) overnight (control), and some of the preparation was subjected to concentration of proteins >3 kDa using concentrated using Amicon Ultra centrifugal concentrators (filtered). ..

    Plasmid Preparation:

    Article Title: Bacterial lipoproteins constitute the TLR2-stimulating activity of Serum Amyloid A
    Article Snippet: Plasmid pcDNA3 was from Invitrogen (Carlsbad, CA). pcDNA3.1(+) encoding human SAA1 was from GenScript (Piscataway, NJ). .. Plasmid pCMV6-XL5 encoding human SAA1 was from Origene. ..



    Similar Products

    94
    TargetMol recombinant human saa1
    Osimertinib upregulates <t>SAA1,</t> which associates with poor clinical outcomes in LUAD. A Schematic of short-term osimertinib exposure (IC 50 , 48 h) in three EGFR-mutant LUAD cell lines (PC-9, HCC827, H1975). Venn diagram illustrates consistently dysregulated secreted-protein genes across the three cell lines. B RNA-seq analysis identifying six differentially expressed secreted-protein genes, with FPKM shown in each dot. C - D Western blot, and ELISA assay validation of SAA1 upregulation, demonstrating a dose-dependent increase in PC-9 and H1975 cells ( n = 3). E Relative cell viability assays confirming ≥ 20-fold resistance to osimertinib in established OR cell lines (PC-9 OR , H1975 OR ) ( n = 3). F - G qPCR and western blot results of SAA1 expression across DTPCs and long-term OR models ( n = 3). H Representative IHC staining of SAA1 in normal lung tissue, LUAD tumors before TKI treatment, and TKI-treated LUAD samples. Scale bar, 20 μm. I Quantification of SAA1 IHC H-scores in paired EGFR-mutant LUAD samples collected before and after neoadjuvant osimertinib treatment ( n = 5). J Western blot analysis of paired EGFR-mutant LUAD tumors before (TKI-naïve) and after osimertinib (TKI-residual) treatment ( n = 5). K Kaplan-Meier analysis of disease-free survival of adjuvant osimertinib-treated LUAD patients ( n = 40). Dunnett’s multiple comparison tests were applied for panels D and F ; two-way ANOVA test for panel E; Paired Student’s t-test for panel I; and log-rank test for panel K. Abbreviations: PR, parental; OR, osimertinib-resistant; DTPC, drug-tolerant persister cells; TKI, tyrosine kinase inhibitor; IHC, immunohistochemistry
    Recombinant Human Saa1, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+saa1/SAA1+Protein%2C+Human%2C+Recombinant/pmc13693122-258-30-37
    Average 94 stars, based on 1 article reviews
    recombinant human saa1 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    MedChemExpress recombinant human saa1 protein
    Osimertinib upregulates <t>SAA1,</t> which associates with poor clinical outcomes in LUAD. A Schematic of short-term osimertinib exposure (IC 50 , 48 h) in three EGFR-mutant LUAD cell lines (PC-9, HCC827, H1975). Venn diagram illustrates consistently dysregulated secreted-protein genes across the three cell lines. B RNA-seq analysis identifying six differentially expressed secreted-protein genes, with FPKM shown in each dot. C - D Western blot, and ELISA assay validation of SAA1 upregulation, demonstrating a dose-dependent increase in PC-9 and H1975 cells ( n = 3). E Relative cell viability assays confirming ≥ 20-fold resistance to osimertinib in established OR cell lines (PC-9 OR , H1975 OR ) ( n = 3). F - G qPCR and western blot results of SAA1 expression across DTPCs and long-term OR models ( n = 3). H Representative IHC staining of SAA1 in normal lung tissue, LUAD tumors before TKI treatment, and TKI-treated LUAD samples. Scale bar, 20 μm. I Quantification of SAA1 IHC H-scores in paired EGFR-mutant LUAD samples collected before and after neoadjuvant osimertinib treatment ( n = 5). J Western blot analysis of paired EGFR-mutant LUAD tumors before (TKI-naïve) and after osimertinib (TKI-residual) treatment ( n = 5). K Kaplan-Meier analysis of disease-free survival of adjuvant osimertinib-treated LUAD patients ( n = 40). Dunnett’s multiple comparison tests were applied for panels D and F ; two-way ANOVA test for panel E; Paired Student’s t-test for panel I; and log-rank test for panel K. Abbreviations: PR, parental; OR, osimertinib-resistant; DTPC, drug-tolerant persister cells; TKI, tyrosine kinase inhibitor; IHC, immunohistochemistry
    Recombinant Human Saa1 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+saa1/SAA1%2C+Human/pm42144065-67-3-11
    Average 93 stars, based on 1 article reviews
    recombinant human saa1 protein - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology recombinant human saa1
    Identification of <t>SAA1‐associated</t> metastatic epithelial subpopulations in ovarian cancer by scRNA‐seq. (A) t‐SNE visualization of cells from paired primary tumours and peritoneal metastases of two patients. (B) Distribution of the ten epithelial clusters in Pri and Meta samples, shown separately. (C) Relative proportions of the ten epithelial clusters in Pri and Meta samples. (D) Pseudotime analysis of epithelial cells from metastases. Left: cells ordered along the inferred trajectory from early (dark) to late (light); the black line indicates the main lineage with bifurcation. Right: same embedding coloured by clusters (0–9). (E) Dot plot showing representative gene expression across the ten clusters; dot size indicates the fraction of expressing cells, and colour denotes average expression. (F) KEGG enrichment of clusters 0, 2, 4 and 6 based on cluster‐specific marker genes. (G) Representative TMA cores stained for SAA1 (green) and nuclei (blue). Scale bar, 200 µm. Quantification of SAA1 + cell percentage in Pri and Meta TMA cores is shown as violin plots with overlaid box plots (Pri, n = 81; Meta, n = 93). p value was determined by the Wilcoxon rank‐sum test, p = 2.9 × 10 − 1 6 . (H) t‐SNE plots showing SAA1 expression in primary (pri) and metastatic (meta) ovarian cancer cells. (I) Kaplan–Meier survival curves in the TCGA‐OV cohort ( n = 429) according to SAA1 expression (log‐rank p = 0.0075). (J) Multivariate Cox regression forest plot identifying independent prognostic factors for ovarian cancer, including SAA1 expression and clinicopathological variables.
    Recombinant Human Saa1, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+saa1/Recombinant+Human+SAA1+Protein/pmc13181338-47-0-3
    Average 94 stars, based on 1 article reviews
    recombinant human saa1 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    R&D Systems human saa1 elisa kit
    Enhanced <t>SAA1</t> expression and NET formation in plasma of MS patients. (A) SAA1 protein expression was quantified by ELISA in plasma samples collected from MS patients and HC. (B) H3.1-nucleosome expression was quantified by ELISA in plasma samples collected from MS patients and HC
    Human Saa1 Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+saa1/Human+Serum+Amyloid+A1+DuoSet+ELISA/pmc13112694-72-1-6
    Average 93 stars, based on 1 article reviews
    human saa1 elisa kit - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    91
    Multi Sciences (Lianke) Biotech Co Ltd enzyme linked immunosorbent assay elisa
    a , b Schematic diagram showing serum cytokine microarray analysis of continuous P2’s serum samples before (PS1 and PS2) or after (PS3, flare; PS4 and PS5, non-flare) the onset of recurrent fever ( a ). PCA analysis of sample variance determined by semi-quantitative 174 cytokines antibody array on serum samples of C1-C3 from three unaffected controls and PS1-PS5 from P2 ( b ). c–e The integrated relative MFI plots of P2’s serum cytokine levels. 26 cytokines peaked in PS3 were enrich in group 1 (left), 24 cytokines higher than control were enriched in group 2 (right) ( c ). The relative MFI was calculated by normalizing the average MFI of the unaffected controls ( n = 3) to 0, and setting the largest MFI to 1 or the smallest MFI to −1 across 5 samples from P2. Boxplots exhibiting expression scores of cytokines of group 1 ( d ) and group 2 ( e ) in indicated cell with Seurat AddModuleScore function. The cell number of each subtype (listed in the “Methods” section), was employed for p value calculations. Boxes show the median (center line), 25th and 75th percentiles (upper and lower hinges), and whiskers extend to 1.5× the interquartile range, representing the maximum and minimum values. f Average expression values (arcsinh transformed) of cl. Casp-3 across identified peripheral immune cell lineages in PBMCs freshly isolated from four unaffected controls (C) and two patients (P, 1 sample from P1 and 2 samples from P2) by mass cytometry by time-of-flight (CyTOF) analysis. g–j Representative contour plots of cl. Casp-3 ( g , h ) and histograms of total RIPK1, pRIPK1(S166) levels ( i , j ) in CD4 + T and CD8 + T cells in freshly isolated PBMCs from unaffected controls (for cl. Casp-3, n = 12; for pRIPK1(S166), n = 10) and patients ( n = 4 for P1 and P2) (left). Summary histograms of cl. Casp-3 and pRIPK1(S166) (right) were shown. k Representative histogram and statistical analysis of surface CD69 expression on CD3 + T cells from unaffected controls ( n = 7) and two patients ( n = 3 for P1 and P2). l Serum IFNγ, sCD25, sCD95 and CD95L of unaffected controls (for IFNγ, n = 9; for sCD25, n = 15; for sCD95 and CD95L, n = 10), two patients (for IFNγ, P1, n = 5, P2 = 6; for sCD25, P1, n = 5, P2, n = 4; for sCD95, P1 and P2, n = 7; for CD95L, P1 = 7; P2 = 8) and their parents (for IFNγ and sCD25, n = 7; for sCD95 and CD95L, n = 6) as well as two CRIA syndrome patients ( n = 6) determined by <t>ELISA.</t> T denotes 10 ng ml -1 TNF; S denotes 250 nM SM164; Z denotes 25 μM z-VAD-fmk. All histogram graphs show mean ± SD. P values were determined by two-tailed unpaired t-test. Data in g–k were pooled from two independent experiments.
    Enzyme Linked Immunosorbent Assay Elisa, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+saa1/Human+Serum+Amyloid+A1+%2FSAA1+ELISA+Kit/pmc13181087-322-8-12
    Average 91 stars, based on 1 article reviews
    enzyme linked immunosorbent assay elisa - by Bioz Stars, 2026-11
    91/100 stars
      Buy from Supplier

    94
    Aviva Systems human serum amyloid a saa1 elisa kit
    Verification of potential biomarkers for AS. (A) Expression levels of <t>SAA1,</t> FERMT3, ILK, and TLN1 in plasma samples from active-stage AS patients, stable-stage AS patients, and healthy controls measured by proteomics. ROC curves for the individual protein (SAA1, FERMT3, ILK, and TLN1) as a predictor to classify AS patients from healthy controls (B), and active-stage AS patients from stable-stage AS patients (C). (D) ELISA analysis of SAA1, FERMT3, ILK, and TLN1 expressions in the plasma samples from an independent validation cohort of healthy controls (N, n = 24), active-stage AS (A, n = 27), and stable-stage AS patients (S, n = 28). Statistical analyses employed Wilcoxon rank-sum test for intergroup comparisons, with results reported as mean ± SEM. Significance thresholds based on BH-adjusted p -values were defined as: *, <0.05; **, <0.01; ***, <0.001.
    Human Serum Amyloid A Saa1 Elisa Kit, supplied by Aviva Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+saa1/SAA+ELISA+Kit+(Human)+%3A+96+Wells+(OKIA00083)/pmc12957791-86-1-12
    Average 94 stars, based on 1 article reviews
    human serum amyloid a saa1 elisa kit - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    OriGene human recombinant saa1 protein
    (A) Cell-cell communication analysis of SAA signaling pathway for the indicated depots and cells. Line colors and widths represent the sending cell and the strength of the signal, respectively. (B) Pseudobulk comparison of differentially expressed genes in epiploic vs. subcutaneous depots, highlighting the indicated signaling pathways. (C) Expression of <t>SAA1</t> mRNA upon stimulation with LPS (10 ng/mL), TNF-α (2.5 ng/mL), IL-1β (10 ng/mL), or IL-6 (10 ng/mL) for 24 h. Data are presented as fold change (FC) over vehicle. Significant (<0.05) p values compared with the vehicle from one-way ANOVA are shown. (D) Relative expression of SAA1 (left) and SAA2 (right) mRNA in adipocytes, ASPCs, adipose-derived endothelial cells (adECs), and THP1-derived macrophages (THP1 M0). Significant (<0.05) p values compared with the cell-type-specific control from one-way ANOVA are shown. (E) Results from ELISA measurements of SAA in conditioned media from human adipocytes incubated without or with LPS for 72 h. Results are displayed as mean, error bars represent standard error of the mean, and statistical significance was calculated using Student’s t test. (F) Analyses of DNA methylation in the indicated cell classes for the promoter and gene body regions of SAA1 and SAA2 , respectively. Chromosomal localization and motifs for NFKB2/RELA/REL and STAT3 are indicated for both genes. (G) SAA1 and SAA2 mRNA expression in adipocytes treated with or without LPS in the presence or absence of different inhibitors described in the main text. Data are presented as FC over vehicle. Significant (<0.05) p values compared with the vehicle from one-way ANOVA are shown. For (C), (D), and (G), data are displayed as geometric mean ± 95% confidence intervals with technical replicates displayed from three independent experiments. ASPC, adipose stromal and progenitor cell.
    Human Recombinant Saa1 Protein, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+saa1/Serum+Amyloid+A+(SAA1)+(NM_000331)+Human+Recombinant+Protein/pmc12989110-39-0-5
    Average 94 stars, based on 1 article reviews
    human recombinant saa1 protein - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    86
    Novoprotein recombinant human saa1
    (A) Cell-cell communication analysis of SAA signaling pathway for the indicated depots and cells. Line colors and widths represent the sending cell and the strength of the signal, respectively. (B) Pseudobulk comparison of differentially expressed genes in epiploic vs. subcutaneous depots, highlighting the indicated signaling pathways. (C) Expression of <t>SAA1</t> mRNA upon stimulation with LPS (10 ng/mL), TNF-α (2.5 ng/mL), IL-1β (10 ng/mL), or IL-6 (10 ng/mL) for 24 h. Data are presented as fold change (FC) over vehicle. Significant (<0.05) p values compared with the vehicle from one-way ANOVA are shown. (D) Relative expression of SAA1 (left) and SAA2 (right) mRNA in adipocytes, ASPCs, adipose-derived endothelial cells (adECs), and THP1-derived macrophages (THP1 M0). Significant (<0.05) p values compared with the cell-type-specific control from one-way ANOVA are shown. (E) Results from ELISA measurements of SAA in conditioned media from human adipocytes incubated without or with LPS for 72 h. Results are displayed as mean, error bars represent standard error of the mean, and statistical significance was calculated using Student’s t test. (F) Analyses of DNA methylation in the indicated cell classes for the promoter and gene body regions of SAA1 and SAA2 , respectively. Chromosomal localization and motifs for NFKB2/RELA/REL and STAT3 are indicated for both genes. (G) SAA1 and SAA2 mRNA expression in adipocytes treated with or without LPS in the presence or absence of different inhibitors described in the main text. Data are presented as FC over vehicle. Significant (<0.05) p values compared with the vehicle from one-way ANOVA are shown. For (C), (D), and (G), data are displayed as geometric mean ± 95% confidence intervals with technical replicates displayed from three independent experiments. ASPC, adipose stromal and progenitor cell.
    Recombinant Human Saa1, supplied by Novoprotein, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+saa1/human+recombinant+saa1/pm41548870-139-24-30
    Average 86 stars, based on 1 article reviews
    recombinant human saa1 - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    93
    Proteintech saa1 rabbit anti human antibody
    A Circle plot summarizing the maximum number of interactions among individual cell types in metastatic lesions. The thickness of the connecting lines represents the interaction strength. B Comparison of the overall information flow, including the number and strength of interactions, within the inferred networks between PTC and metastatic lesions. C Heatmap displaying the potential outgoing and incoming interaction strength of each cellular cluster in PTC and metastatic lesions. D Heatmap illustrating the relative signaling contribution of each cell group based on the number and strength of interactions, comparing PTC with metastatic lesions. E Differential network centrality analysis based on EMT-like cancer-associated fibroblasts (CAFs), comparing PTC and metastatic lesions. F Bubble heatmap showing the cell-cell communication of selected ligand-receptor pairs between EMT-like CAFs and CD8 + PDCD1 + T cells. Dot size indicates the P -value, while color represents the communication probability. G Multiplex immunohistochemistry (mIHC) validation of the cross-talk between <t>SAA1+</t> CAFs and T cells via the PPIA-BSG ligand-receptor interaction.
    Saa1 Rabbit Anti Human Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+saa1/SAA+Antibody/pmc12658061-228-92-96
    Average 93 stars, based on 1 article reviews
    saa1 rabbit anti human antibody - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    R&D Systems human saa1 duoset elisa
    TGFβ1 signaling in primary CRC and LM-CRC CAFs induces expression of IL-6 (A) Schematic overview of workflow for CAF isolation and TGFβ1 pathway-targeted qPCR array. (B) RNA expression of TGFβ1 target genes in two primary CRC CAFs (CAF1 and CAF2) and one LM-CRC CAF. qPCR values have been log transformed. (C) Numerical values depicting the seven TGFβ1 target genes that showed consistent upregulation. (D) Fold change RNA expression of these seven TGFβ1 target genes (yellow symbols). (E) IL6 RNA expression in primary CRC CAFs (CAF4 and CAF5) and the CCD-18Co colon fibroblast line after stimulation with TGFβ1 or medium control. N = 3 CCD-18Co, CAF4; N = 2 CAF5 independent biological experiments. ∗∗ p ≤ 0.01 determined by paired T test. (F) Protein expression of IL-6 in tissue lysates of normal colon and primary CRC (left panel, N = 50) or normal liver and LM-CRC (right panel, N = 50) as determined by <t>ELISA.</t> ∗∗∗∗ p ≤ 0.0001, ∗ p ≤ 0.05 determined by unpaired T test. (G) IL6 RNA expression in unstimulated normal colon fibroblasts ( N = 8) or primary CRC CAFs ( N = 10). (H) RNA expression of IL6 in the original CMS classified cohort (CMS1: N = 457; CMS2: N = 1183; CMS3: N = 409; CMS4: N = 773). ∗∗∗∗ p ≤ 0.0001 determined by one-way ANOVA with correction for multiple testing (Dunnett’s test).
    Human Saa1 Duoset Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+saa1/Human+Serum+Amyloid+A1+DuoSet+ELISA/pmc12596662-306-12-16
    Average 93 stars, based on 1 article reviews
    human saa1 duoset elisa - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    Image Search Results


    Osimertinib upregulates SAA1, which associates with poor clinical outcomes in LUAD. A Schematic of short-term osimertinib exposure (IC 50 , 48 h) in three EGFR-mutant LUAD cell lines (PC-9, HCC827, H1975). Venn diagram illustrates consistently dysregulated secreted-protein genes across the three cell lines. B RNA-seq analysis identifying six differentially expressed secreted-protein genes, with FPKM shown in each dot. C - D Western blot, and ELISA assay validation of SAA1 upregulation, demonstrating a dose-dependent increase in PC-9 and H1975 cells ( n = 3). E Relative cell viability assays confirming ≥ 20-fold resistance to osimertinib in established OR cell lines (PC-9 OR , H1975 OR ) ( n = 3). F - G qPCR and western blot results of SAA1 expression across DTPCs and long-term OR models ( n = 3). H Representative IHC staining of SAA1 in normal lung tissue, LUAD tumors before TKI treatment, and TKI-treated LUAD samples. Scale bar, 20 μm. I Quantification of SAA1 IHC H-scores in paired EGFR-mutant LUAD samples collected before and after neoadjuvant osimertinib treatment ( n = 5). J Western blot analysis of paired EGFR-mutant LUAD tumors before (TKI-naïve) and after osimertinib (TKI-residual) treatment ( n = 5). K Kaplan-Meier analysis of disease-free survival of adjuvant osimertinib-treated LUAD patients ( n = 40). Dunnett’s multiple comparison tests were applied for panels D and F ; two-way ANOVA test for panel E; Paired Student’s t-test for panel I; and log-rank test for panel K. Abbreviations: PR, parental; OR, osimertinib-resistant; DTPC, drug-tolerant persister cells; TKI, tyrosine kinase inhibitor; IHC, immunohistochemistry

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    Article Title: ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma

    doi: 10.1186/s13046-026-03792-6

    Figure Lengend Snippet: Osimertinib upregulates SAA1, which associates with poor clinical outcomes in LUAD. A Schematic of short-term osimertinib exposure (IC 50 , 48 h) in three EGFR-mutant LUAD cell lines (PC-9, HCC827, H1975). Venn diagram illustrates consistently dysregulated secreted-protein genes across the three cell lines. B RNA-seq analysis identifying six differentially expressed secreted-protein genes, with FPKM shown in each dot. C - D Western blot, and ELISA assay validation of SAA1 upregulation, demonstrating a dose-dependent increase in PC-9 and H1975 cells ( n = 3). E Relative cell viability assays confirming ≥ 20-fold resistance to osimertinib in established OR cell lines (PC-9 OR , H1975 OR ) ( n = 3). F - G qPCR and western blot results of SAA1 expression across DTPCs and long-term OR models ( n = 3). H Representative IHC staining of SAA1 in normal lung tissue, LUAD tumors before TKI treatment, and TKI-treated LUAD samples. Scale bar, 20 μm. I Quantification of SAA1 IHC H-scores in paired EGFR-mutant LUAD samples collected before and after neoadjuvant osimertinib treatment ( n = 5). J Western blot analysis of paired EGFR-mutant LUAD tumors before (TKI-naïve) and after osimertinib (TKI-residual) treatment ( n = 5). K Kaplan-Meier analysis of disease-free survival of adjuvant osimertinib-treated LUAD patients ( n = 40). Dunnett’s multiple comparison tests were applied for panels D and F ; two-way ANOVA test for panel E; Paired Student’s t-test for panel I; and log-rank test for panel K. Abbreviations: PR, parental; OR, osimertinib-resistant; DTPC, drug-tolerant persister cells; TKI, tyrosine kinase inhibitor; IHC, immunohistochemistry

    Article Snippet: Osimertinib (T2490), gefitinib (T1181), afatinib ( T21312 ), the NF-κB inhibitor BAY 11-7082 (T1902), the TLR2 inhibitor C29 (T3502), the TLR4 inhibitor TAK-242 (TQ0181), the ERK inhibitor SCH772984 (T6066), and recombinant human SAA1 (TMPJ-00480) were purchased from TargetMol (Boston, MA, USA).

    Techniques: Mutagenesis, RNA Sequencing, Analysis, Western Blot, Enzyme-linked Immunosorbent Assay, Biomarker Discovery, Expressing, Immunohistochemistry, Tissue, Adjuvant, Comparison

    SAA1 is required for both drug tolerance and established osimertinib resistance. A - B Relative cell viability and proliferation assays with different generations of EGFR-TKI (10 nM) in parental EGFR-mutant LUAD cell lines transfected with two independent siRNAs targeting SAA1 in PC-9 and H1975 cells ( n = 3). C Western blot confirming the establishment of SAA1-OE and SAA1-KO OR cell models generated by lentiviral transduction. D - E Relative cell viability and proliferation assays (10 nM) with different generations of EGFR-TKI in SAA1-OE, SAA1-KO OR models, and SAA1-KO cells rescued with exogenous SAA1 (100 ng/ml) ( n = 3). F Quantification of DTPC formation efficiency in LUAD cells treated with PBS or exogenous SAA1 (100 ng/ml) ( n = 3). G - H In vivo assessment using a PC-9 OR CDX model established with cells transduced with either a negative control vector or SAA1-KO lentivirus. Mice received daily oral gavage of osimertinib (5 mg/kg) or saline for 9 consecutive days ( n = 6). Tumor growth curves ( G ) and representative final tumor specimens ( H ) are shown. Dunnett’s multiple comparison tests were used for panels B and E , and two-way ANOVA test was applied for panel G . Abbreviations: SAA1-OE, SAA1 overexpression; SAA1-KO, SAA1 knockout; OR, osimertinib-resistant; Osi, osimertinib; Gef, gefitinib; Afa, afatinib; TKI, tyrosine kinase inhibitor; DTPC, drug-tolerant persister cells

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    Article Title: ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma

    doi: 10.1186/s13046-026-03792-6

    Figure Lengend Snippet: SAA1 is required for both drug tolerance and established osimertinib resistance. A - B Relative cell viability and proliferation assays with different generations of EGFR-TKI (10 nM) in parental EGFR-mutant LUAD cell lines transfected with two independent siRNAs targeting SAA1 in PC-9 and H1975 cells ( n = 3). C Western blot confirming the establishment of SAA1-OE and SAA1-KO OR cell models generated by lentiviral transduction. D - E Relative cell viability and proliferation assays (10 nM) with different generations of EGFR-TKI in SAA1-OE, SAA1-KO OR models, and SAA1-KO cells rescued with exogenous SAA1 (100 ng/ml) ( n = 3). F Quantification of DTPC formation efficiency in LUAD cells treated with PBS or exogenous SAA1 (100 ng/ml) ( n = 3). G - H In vivo assessment using a PC-9 OR CDX model established with cells transduced with either a negative control vector or SAA1-KO lentivirus. Mice received daily oral gavage of osimertinib (5 mg/kg) or saline for 9 consecutive days ( n = 6). Tumor growth curves ( G ) and representative final tumor specimens ( H ) are shown. Dunnett’s multiple comparison tests were used for panels B and E , and two-way ANOVA test was applied for panel G . Abbreviations: SAA1-OE, SAA1 overexpression; SAA1-KO, SAA1 knockout; OR, osimertinib-resistant; Osi, osimertinib; Gef, gefitinib; Afa, afatinib; TKI, tyrosine kinase inhibitor; DTPC, drug-tolerant persister cells

    Article Snippet: Osimertinib (T2490), gefitinib (T1181), afatinib ( T21312 ), the NF-κB inhibitor BAY 11-7082 (T1902), the TLR2 inhibitor C29 (T3502), the TLR4 inhibitor TAK-242 (TQ0181), the ERK inhibitor SCH772984 (T6066), and recombinant human SAA1 (TMPJ-00480) were purchased from TargetMol (Boston, MA, USA).

    Techniques: Mutagenesis, Transfection, Western Blot, Generated, Transduction, In Vivo, Negative Control, Plasmid Preparation, Saline, Comparison, Over Expression, Knock-Out

    SAA1 activates the TLR4/NF-κB pathway to drive osimertinib resistance. A Heatmap showing the expression patterns of NF-κB-associated genes in PC-9 cells treated with exogenous SAA1 (100 ng/ml, 24 h) compared with PBS. B GSEA plot indicating enrichment of the NF-κB signaling pathway in SAA1-treated PC-9 cells. C - D Western blot analysis of whole-cell lysates ( C , assessing p65, p-p65, IκBα, and p-IκBα) and subcellular fractions ( D , assessing nuclear and cytoplasmic p65) in PC-9 OR and H1975 OR cells transfected with vector control, SAA1 overexpression, SAA1 knockout, or SAA1 knockout rescued with exogenous SAA1. E - F Western blot evaluating the effect of the NF-κB inhibitor BAY 11-7082 (5 µM) on SAA1-induced pathway activation in whole-cell lysates ( E ) and subcellular fractions ( F ). G - H Western blot evaluating the effect of the TLR4 inhibitor TAK-242 (10 µM) on SAA1-induced pathway activation in whole-cell lysates ( G ) and subcellular fractions ( H ). I - L Cell proliferation curves ( I , K ) and relative cell viability assays determining osimertinib IC50 ( J , L ) in PC-9 OR and H1975 OR cells treated with PBS or exogenous SAA1, in the presence or absence of BAY 11-7082 (5 µM) or TAK-242 (10 µM) ( n = 3). Two-way ANOVA tests were applied for panels I - L . Abbreviations: SAA1-OE, SAA1 overexpression; SAA1-KO, SAA1 knockout; OR, osimertinib-resistant; NF-κBi, NF-κB inhibitor; TLR4i, TLR4 inhibitor

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    Article Title: ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma

    doi: 10.1186/s13046-026-03792-6

    Figure Lengend Snippet: SAA1 activates the TLR4/NF-κB pathway to drive osimertinib resistance. A Heatmap showing the expression patterns of NF-κB-associated genes in PC-9 cells treated with exogenous SAA1 (100 ng/ml, 24 h) compared with PBS. B GSEA plot indicating enrichment of the NF-κB signaling pathway in SAA1-treated PC-9 cells. C - D Western blot analysis of whole-cell lysates ( C , assessing p65, p-p65, IκBα, and p-IκBα) and subcellular fractions ( D , assessing nuclear and cytoplasmic p65) in PC-9 OR and H1975 OR cells transfected with vector control, SAA1 overexpression, SAA1 knockout, or SAA1 knockout rescued with exogenous SAA1. E - F Western blot evaluating the effect of the NF-κB inhibitor BAY 11-7082 (5 µM) on SAA1-induced pathway activation in whole-cell lysates ( E ) and subcellular fractions ( F ). G - H Western blot evaluating the effect of the TLR4 inhibitor TAK-242 (10 µM) on SAA1-induced pathway activation in whole-cell lysates ( G ) and subcellular fractions ( H ). I - L Cell proliferation curves ( I , K ) and relative cell viability assays determining osimertinib IC50 ( J , L ) in PC-9 OR and H1975 OR cells treated with PBS or exogenous SAA1, in the presence or absence of BAY 11-7082 (5 µM) or TAK-242 (10 µM) ( n = 3). Two-way ANOVA tests were applied for panels I - L . Abbreviations: SAA1-OE, SAA1 overexpression; SAA1-KO, SAA1 knockout; OR, osimertinib-resistant; NF-κBi, NF-κB inhibitor; TLR4i, TLR4 inhibitor

    Article Snippet: Osimertinib (T2490), gefitinib (T1181), afatinib ( T21312 ), the NF-κB inhibitor BAY 11-7082 (T1902), the TLR2 inhibitor C29 (T3502), the TLR4 inhibitor TAK-242 (TQ0181), the ERK inhibitor SCH772984 (T6066), and recombinant human SAA1 (TMPJ-00480) were purchased from TargetMol (Boston, MA, USA).

    Techniques: Expressing, Western Blot, Analysis, Transfection, Plasmid Preparation, Control, Over Expression, Knock-Out, Activation Assay

    SAA1 reshapes the tumor microenvironment by promoting macrophage recruitment and pro-tumorigenic polarization. A - B Representative immunofluorescence images ( A ) and corresponding quantification ( B ) of F4/80⁺ (green) and CD206⁺ (yellow) macrophages in tumors from PC-9 OR CDX models treated with vehicle or osimertinib, comparing vector control and SAA1-KO groups. Scale bar, 20 μm. C - D Flow cytometry plots ( D ) and statistical quantification ( C ) of M2 macrophage polarization (CD206⁺) in BMDM and THP-1 cells treated with PBS or exogenous SAA1 (100 ng/ml, 24 h). E qPCR analysis of classical M2 macrophage markers ( CD206 , VEGFA , TGFB1 , IL-10 , ARG1 ) in THP-1 and BMDM cells co-cultured with PC-9 OR cell lines under osimertinib treatment, comparing vector control and SAA1 knockout conditions ( n = 3). F qPCR analysis of newly proposed macrophage markers ( SPP1 , C1QC , ISG15 , FN1 ) in THP-1 and BMDM cells after exposure to exogenous SAA1(100 ng/ml, 24 h) ( n = 3). G qPCR analysis of M2 markers and SPP1 in THP-1 and BMDM cells treated with TAK-242 (10 µM, 24 h), with or without exogenous SAA1 (100 ng/ml, 24 h) ( n = 3). H - I Flow cytometry analysis ( H ) and comprehensive quantification ( I ) of CD206⁺ macrophages in THP-1 cells treated with PBS or exogenous SAA1 (100 ng/ml, 24 h), combined with DMSO, TAK-242 (10 µM, 24 h), or C29 (50 µM, 24 h), demonstrating the comparative blockade efficacy of distinct TLR pathways ( n = 3). J - L Representative multiplex immunofluorescence images ( L ) and quantitative analysis ( J , K ) of CD68⁺ (red), CD206⁺ (green), and SPP1⁺ (yellow) macrophage infiltration in paired LUAD patient samples before (TKI-naïve) and after (TKI-residual) osimertinib therapy. Scale bar, 50 μm. Student’s t-tests were for panels C , F , J , K and one-way or two-way ANOVA with Dunnett’s multiple comparison tests were for panels B, E, G, I. Abbreviations: OR, osimertinib-resistant; SAA1-KO, SAA1 knockout; Exo, exogenous; TKI, tyrosine kinase inhibitor; IHC, immunohistochemistry

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    Article Title: ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma

    doi: 10.1186/s13046-026-03792-6

    Figure Lengend Snippet: SAA1 reshapes the tumor microenvironment by promoting macrophage recruitment and pro-tumorigenic polarization. A - B Representative immunofluorescence images ( A ) and corresponding quantification ( B ) of F4/80⁺ (green) and CD206⁺ (yellow) macrophages in tumors from PC-9 OR CDX models treated with vehicle or osimertinib, comparing vector control and SAA1-KO groups. Scale bar, 20 μm. C - D Flow cytometry plots ( D ) and statistical quantification ( C ) of M2 macrophage polarization (CD206⁺) in BMDM and THP-1 cells treated with PBS or exogenous SAA1 (100 ng/ml, 24 h). E qPCR analysis of classical M2 macrophage markers ( CD206 , VEGFA , TGFB1 , IL-10 , ARG1 ) in THP-1 and BMDM cells co-cultured with PC-9 OR cell lines under osimertinib treatment, comparing vector control and SAA1 knockout conditions ( n = 3). F qPCR analysis of newly proposed macrophage markers ( SPP1 , C1QC , ISG15 , FN1 ) in THP-1 and BMDM cells after exposure to exogenous SAA1(100 ng/ml, 24 h) ( n = 3). G qPCR analysis of M2 markers and SPP1 in THP-1 and BMDM cells treated with TAK-242 (10 µM, 24 h), with or without exogenous SAA1 (100 ng/ml, 24 h) ( n = 3). H - I Flow cytometry analysis ( H ) and comprehensive quantification ( I ) of CD206⁺ macrophages in THP-1 cells treated with PBS or exogenous SAA1 (100 ng/ml, 24 h), combined with DMSO, TAK-242 (10 µM, 24 h), or C29 (50 µM, 24 h), demonstrating the comparative blockade efficacy of distinct TLR pathways ( n = 3). J - L Representative multiplex immunofluorescence images ( L ) and quantitative analysis ( J , K ) of CD68⁺ (red), CD206⁺ (green), and SPP1⁺ (yellow) macrophage infiltration in paired LUAD patient samples before (TKI-naïve) and after (TKI-residual) osimertinib therapy. Scale bar, 50 μm. Student’s t-tests were for panels C , F , J , K and one-way or two-way ANOVA with Dunnett’s multiple comparison tests were for panels B, E, G, I. Abbreviations: OR, osimertinib-resistant; SAA1-KO, SAA1 knockout; Exo, exogenous; TKI, tyrosine kinase inhibitor; IHC, immunohistochemistry

    Article Snippet: Osimertinib (T2490), gefitinib (T1181), afatinib ( T21312 ), the NF-κB inhibitor BAY 11-7082 (T1902), the TLR2 inhibitor C29 (T3502), the TLR4 inhibitor TAK-242 (TQ0181), the ERK inhibitor SCH772984 (T6066), and recombinant human SAA1 (TMPJ-00480) were purchased from TargetMol (Boston, MA, USA).

    Techniques: Immunofluorescence, Plasmid Preparation, Control, Flow Cytometry, Analysis, Cell Culture, Knock-Out, Multiplex Assay, Comparison, Immunohistochemistry, Co-Culture

    GATAD2A S114 phosphorylation modulates NuRD complex integrity and regulates SAA1 expression. A DNA pull-down assay using a biotin-labeled SAA1 promoter probe (-1000 to + 200 bp) incubated with PC-9 nuclear extracts. Mass spectrometry identified 41 transcription factors, five of which (RXRA, YY1, ETV6, MAX, GATAD2A) were selected based on ENCODE ChIP-seq data. B qPCR of SAA1 expression following two individual siRNA knockdown of the five candidate transcription factors in PC-9 cells ( n = 3). C , D qPCR and western blot of SAA1 levels in PC-9 and H1975 cells transfected with two independent siRNAs targeting GATAD2A ( n = 3). E Predicted GATAD2A binding motif and binding peaks in the SAA1 promoter region from public ChIP-seq datasets, with indicated the location of the primer used for ChIP-qPCR validation. F ChIP-qPCR of GATAD2A occupancy at the SAA1 promoter in PC-9 and H1975 cells compared with IgG controls ( n = 3). G Luciferase reporter assay of wild-type and mutant SAA1 promoters in PC-9 and H1975 cells following GATAD2A knockdown ( n = 3). H Phosphoproteomic mapping of GATAD2A in PC-9 parental and OR cells, showing phosphorylated residues including S107, S110 and S114, among which S114 was predicted to be phosphorylated by ERK. I SAA1 expression in PC-9 and H1975 cells harboring the GATAD2A S114A knock-in compared with wild-type cells following osimertinib treatment (10 nM, 48 h). J Co-immunoprecipitation analysis of GATAD2A interactions with MBD2 and MTA2 in PC-9 and H1975 cells under different treatments, including osimertinib (10 nM, 48 h), SCH772984 (ERK inhibitor) (10 µM, 48 h), and S114A mutation. K Quantitative analysis of the PLA signals representing GATAD2A-NuRD complex interactions in PC-9 and H1975 cells under the indicated conditions ( n = 3). L PLA showing GATAD2A-NuRD component interactions under the same conditions as panel J . Dunnett’s multiple comparison tests were applied for panels B , C , G , and K ; Student’s t-test for panel F . Abbreviations: TF, transcription factors; ChIP, chromatin immunoprecipitation; PLA, proximity ligation assay; NuRD, nucleosome remodeling and deacetylase complex

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    Article Title: ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma

    doi: 10.1186/s13046-026-03792-6

    Figure Lengend Snippet: GATAD2A S114 phosphorylation modulates NuRD complex integrity and regulates SAA1 expression. A DNA pull-down assay using a biotin-labeled SAA1 promoter probe (-1000 to + 200 bp) incubated with PC-9 nuclear extracts. Mass spectrometry identified 41 transcription factors, five of which (RXRA, YY1, ETV6, MAX, GATAD2A) were selected based on ENCODE ChIP-seq data. B qPCR of SAA1 expression following two individual siRNA knockdown of the five candidate transcription factors in PC-9 cells ( n = 3). C , D qPCR and western blot of SAA1 levels in PC-9 and H1975 cells transfected with two independent siRNAs targeting GATAD2A ( n = 3). E Predicted GATAD2A binding motif and binding peaks in the SAA1 promoter region from public ChIP-seq datasets, with indicated the location of the primer used for ChIP-qPCR validation. F ChIP-qPCR of GATAD2A occupancy at the SAA1 promoter in PC-9 and H1975 cells compared with IgG controls ( n = 3). G Luciferase reporter assay of wild-type and mutant SAA1 promoters in PC-9 and H1975 cells following GATAD2A knockdown ( n = 3). H Phosphoproteomic mapping of GATAD2A in PC-9 parental and OR cells, showing phosphorylated residues including S107, S110 and S114, among which S114 was predicted to be phosphorylated by ERK. I SAA1 expression in PC-9 and H1975 cells harboring the GATAD2A S114A knock-in compared with wild-type cells following osimertinib treatment (10 nM, 48 h). J Co-immunoprecipitation analysis of GATAD2A interactions with MBD2 and MTA2 in PC-9 and H1975 cells under different treatments, including osimertinib (10 nM, 48 h), SCH772984 (ERK inhibitor) (10 µM, 48 h), and S114A mutation. K Quantitative analysis of the PLA signals representing GATAD2A-NuRD complex interactions in PC-9 and H1975 cells under the indicated conditions ( n = 3). L PLA showing GATAD2A-NuRD component interactions under the same conditions as panel J . Dunnett’s multiple comparison tests were applied for panels B , C , G , and K ; Student’s t-test for panel F . Abbreviations: TF, transcription factors; ChIP, chromatin immunoprecipitation; PLA, proximity ligation assay; NuRD, nucleosome remodeling and deacetylase complex

    Article Snippet: Osimertinib (T2490), gefitinib (T1181), afatinib ( T21312 ), the NF-κB inhibitor BAY 11-7082 (T1902), the TLR2 inhibitor C29 (T3502), the TLR4 inhibitor TAK-242 (TQ0181), the ERK inhibitor SCH772984 (T6066), and recombinant human SAA1 (TMPJ-00480) were purchased from TargetMol (Boston, MA, USA).

    Techniques: Phospho-proteomics, Expressing, Pull Down Assay, Labeling, Incubation, Mass Spectrometry, ChIP-sequencing, Knockdown, Western Blot, Transfection, Binding Assay, ChIP-qPCR, Biomarker Discovery, Luciferase, Reporter Assay, Mutagenesis, Knock-In, Co-Immunoprecipitation Assay, Analysis, Comparison, Chromatin Immunoprecipitation, Proximity Ligation Assay, Histone Deacetylase Assay

    Preclinical evaluation of Anti-SAA1 neutralization in EGFR-mutant models. A Proliferation curves of PC-9 OR and H1975 OR cells treated with Anti-SAA1 (1 µg/mL) or isotype IgG control across the indicated time points ( n = 3). B Relative cell viability of PC-9 OR and H1975 OR cells following Anti-SAA1 (1 µg/mL) or IgG treatment ( n = 3). C - D Representative tumor images ( C ) and tumor growth curves ( D ) of PC-9 OR -derived CDX models treated with control therapy, Anti-SAA1, osimertinib, or the combination ( n = 6). Mice were administered daily oral gavage of osimertinib (5 mg/kg) or saline for nine consecutive days. In parallel, intraperitoneal injections of Anti-SAA1 (0.25 µg/g) or control IgG were given every three days ( n = 6). E Morphological features of PDOs treated with IgG, Anti-SAA1 (1 µg/mL) combined with either saline or osimertinib (10 nM). Scale bar, 20 μm. F ATP levels in corresponding PDOs under the indicated treatment conditions ( n = 3). G Representative tumor images of PDX models treated with control therapy, Anti-SAA1, osimertinib, or the combination ( n = 3 for each PDX). H Schematic of tumor induction in the h EGFR L858R/T790M genetically engineered mouse model using intratracheal AAV- Scgb1a1 -Cre delivery. I Micro-CT-based quantification of tumor burden after 4 weeks since treatment with osimertinib alone, Anti-SAA1 plus osimertinib, or isotype control. 30-days after AAV delivery, mice were administered osimertinib (5 mg/kg) or saline by daily oral gavage for 21 consecutive days. In addition, intraperitoneal injections of Anti-SAA1 (0.25 µg/g) or control IgG were given every three days, for a total of six doses. J Survival curves of mice receiving the indicated treatments ( n = 6). K Representative immunohistochemical and multiplex immunofluorescence images of lung tumor sections derived from immunocompetent GEMM models following the indicated treatments. DAPI (blue), F4/80 (magenta), CD206 (green), SPP1 (red), and CD8 (yellow). Scale bars, 50 μm. L - M Quantitative analyses of the percentage of immunosuppressive SPP1 + CD206 + subpopulations among total F4/80 + macrophages ( L ) and the infiltration rate of CD8 + T cells among total DAPI + cells ( M ) in the spontaneous tumor tissues ( n = 6). Two-way ANOVA for panels A , B , and D ; Dunnett’s multiple comparison test was applied for panel F , log-rank test for panel J , and one-way ANOVA for panels L and M . Abbreviations: Anti-SAA1, SAA1 neutralizing antibody; OR, osimertinib-resistant; CDX, cell-derived xenograft; PDO, patient-derived organoid; PDX, patient-derived xenograft; AAV, adeno-associated virus; micro-CT, micro-computed tomography

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    Article Title: ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma

    doi: 10.1186/s13046-026-03792-6

    Figure Lengend Snippet: Preclinical evaluation of Anti-SAA1 neutralization in EGFR-mutant models. A Proliferation curves of PC-9 OR and H1975 OR cells treated with Anti-SAA1 (1 µg/mL) or isotype IgG control across the indicated time points ( n = 3). B Relative cell viability of PC-9 OR and H1975 OR cells following Anti-SAA1 (1 µg/mL) or IgG treatment ( n = 3). C - D Representative tumor images ( C ) and tumor growth curves ( D ) of PC-9 OR -derived CDX models treated with control therapy, Anti-SAA1, osimertinib, or the combination ( n = 6). Mice were administered daily oral gavage of osimertinib (5 mg/kg) or saline for nine consecutive days. In parallel, intraperitoneal injections of Anti-SAA1 (0.25 µg/g) or control IgG were given every three days ( n = 6). E Morphological features of PDOs treated with IgG, Anti-SAA1 (1 µg/mL) combined with either saline or osimertinib (10 nM). Scale bar, 20 μm. F ATP levels in corresponding PDOs under the indicated treatment conditions ( n = 3). G Representative tumor images of PDX models treated with control therapy, Anti-SAA1, osimertinib, or the combination ( n = 3 for each PDX). H Schematic of tumor induction in the h EGFR L858R/T790M genetically engineered mouse model using intratracheal AAV- Scgb1a1 -Cre delivery. I Micro-CT-based quantification of tumor burden after 4 weeks since treatment with osimertinib alone, Anti-SAA1 plus osimertinib, or isotype control. 30-days after AAV delivery, mice were administered osimertinib (5 mg/kg) or saline by daily oral gavage for 21 consecutive days. In addition, intraperitoneal injections of Anti-SAA1 (0.25 µg/g) or control IgG were given every three days, for a total of six doses. J Survival curves of mice receiving the indicated treatments ( n = 6). K Representative immunohistochemical and multiplex immunofluorescence images of lung tumor sections derived from immunocompetent GEMM models following the indicated treatments. DAPI (blue), F4/80 (magenta), CD206 (green), SPP1 (red), and CD8 (yellow). Scale bars, 50 μm. L - M Quantitative analyses of the percentage of immunosuppressive SPP1 + CD206 + subpopulations among total F4/80 + macrophages ( L ) and the infiltration rate of CD8 + T cells among total DAPI + cells ( M ) in the spontaneous tumor tissues ( n = 6). Two-way ANOVA for panels A , B , and D ; Dunnett’s multiple comparison test was applied for panel F , log-rank test for panel J , and one-way ANOVA for panels L and M . Abbreviations: Anti-SAA1, SAA1 neutralizing antibody; OR, osimertinib-resistant; CDX, cell-derived xenograft; PDO, patient-derived organoid; PDX, patient-derived xenograft; AAV, adeno-associated virus; micro-CT, micro-computed tomography

    Article Snippet: Osimertinib (T2490), gefitinib (T1181), afatinib ( T21312 ), the NF-κB inhibitor BAY 11-7082 (T1902), the TLR2 inhibitor C29 (T3502), the TLR4 inhibitor TAK-242 (TQ0181), the ERK inhibitor SCH772984 (T6066), and recombinant human SAA1 (TMPJ-00480) were purchased from TargetMol (Boston, MA, USA).

    Techniques: Neutralization, Mutagenesis, Control, Derivative Assay, Saline, Micro-CT, Immunohistochemical staining, Multiplex Assay, Immunofluorescence, Comparison, Xenograft Assay, Virus

    Schematic representation illustrating the mechanism of the ERK/GATAD2A/SAA1 axis in driving osimertinib resistance in EGFR-mutated lung adenocarcinoma. The targeted inhibition of mutant EGFR by osimertinib suppresses downstream ERK signaling. This reduction in ERK kinase activity leads to the dephosphorylation of the epigenetic regulator GATAD2A at the S114 site. In its dephosphorylated state, GATAD2A fails to maintain the assembly of the NuRD corepressor complex at the SAA1 promoter. The dissociation of the NuRD complex relieves the epigenetic silencing of the SAA1 gene, resulting in robust transcriptional derepression and the subsequent secretion of SAA1 protein into the extracellular space. Once secreted, SAA1 functions as a dual-modal mediator to orchestrate acquired resistance. Autocrinely, SAA1 binds to TLR4 on the tumor cell membrane, triggering the intracellular NF-κB signaling cascade to promote tumor cell survival and persistence. Paracrinely, SAA1 remodels the tumor microenvironment by promoting the polarization of macrophages toward an immunosuppressive pro-tumor phenotype. Therapeutic intervention with an anti-SAA1 neutralizing antibody effectively intercepts these extracellular signals, abrogating both the tumor-intrinsic NF-κB survival pathway and the macrophage-mediated immune evasion, thereby restoring sensitivity to osimertinib

    Journal: Journal of Experimental & Clinical Cancer Research : CR

    Article Title: ERK/GATAD2A/SAA1 axis drives osimertinib resistance via NF-κB and macrophage reprogramming in EGFR-mutated lung adenocarcinoma

    doi: 10.1186/s13046-026-03792-6

    Figure Lengend Snippet: Schematic representation illustrating the mechanism of the ERK/GATAD2A/SAA1 axis in driving osimertinib resistance in EGFR-mutated lung adenocarcinoma. The targeted inhibition of mutant EGFR by osimertinib suppresses downstream ERK signaling. This reduction in ERK kinase activity leads to the dephosphorylation of the epigenetic regulator GATAD2A at the S114 site. In its dephosphorylated state, GATAD2A fails to maintain the assembly of the NuRD corepressor complex at the SAA1 promoter. The dissociation of the NuRD complex relieves the epigenetic silencing of the SAA1 gene, resulting in robust transcriptional derepression and the subsequent secretion of SAA1 protein into the extracellular space. Once secreted, SAA1 functions as a dual-modal mediator to orchestrate acquired resistance. Autocrinely, SAA1 binds to TLR4 on the tumor cell membrane, triggering the intracellular NF-κB signaling cascade to promote tumor cell survival and persistence. Paracrinely, SAA1 remodels the tumor microenvironment by promoting the polarization of macrophages toward an immunosuppressive pro-tumor phenotype. Therapeutic intervention with an anti-SAA1 neutralizing antibody effectively intercepts these extracellular signals, abrogating both the tumor-intrinsic NF-κB survival pathway and the macrophage-mediated immune evasion, thereby restoring sensitivity to osimertinib

    Article Snippet: Osimertinib (T2490), gefitinib (T1181), afatinib ( T21312 ), the NF-κB inhibitor BAY 11-7082 (T1902), the TLR2 inhibitor C29 (T3502), the TLR4 inhibitor TAK-242 (TQ0181), the ERK inhibitor SCH772984 (T6066), and recombinant human SAA1 (TMPJ-00480) were purchased from TargetMol (Boston, MA, USA).

    Techniques: Inhibition, Mutagenesis, Activity Assay, De-Phosphorylation Assay, Membrane, Sensitivity

    Identification of SAA1‐associated metastatic epithelial subpopulations in ovarian cancer by scRNA‐seq. (A) t‐SNE visualization of cells from paired primary tumours and peritoneal metastases of two patients. (B) Distribution of the ten epithelial clusters in Pri and Meta samples, shown separately. (C) Relative proportions of the ten epithelial clusters in Pri and Meta samples. (D) Pseudotime analysis of epithelial cells from metastases. Left: cells ordered along the inferred trajectory from early (dark) to late (light); the black line indicates the main lineage with bifurcation. Right: same embedding coloured by clusters (0–9). (E) Dot plot showing representative gene expression across the ten clusters; dot size indicates the fraction of expressing cells, and colour denotes average expression. (F) KEGG enrichment of clusters 0, 2, 4 and 6 based on cluster‐specific marker genes. (G) Representative TMA cores stained for SAA1 (green) and nuclei (blue). Scale bar, 200 µm. Quantification of SAA1 + cell percentage in Pri and Meta TMA cores is shown as violin plots with overlaid box plots (Pri, n = 81; Meta, n = 93). p value was determined by the Wilcoxon rank‐sum test, p = 2.9 × 10 − 1 6 . (H) t‐SNE plots showing SAA1 expression in primary (pri) and metastatic (meta) ovarian cancer cells. (I) Kaplan–Meier survival curves in the TCGA‐OV cohort ( n = 429) according to SAA1 expression (log‐rank p = 0.0075). (J) Multivariate Cox regression forest plot identifying independent prognostic factors for ovarian cancer, including SAA1 expression and clinicopathological variables.

    Journal: Clinical and Translational Medicine

    Article Title: Tumour‐derived SAA1 reprogrammes macrophages to promote CXCL1‐mediated metastasis in Ovarian Cancer

    doi: 10.1002/ctm2.70698

    Figure Lengend Snippet: Identification of SAA1‐associated metastatic epithelial subpopulations in ovarian cancer by scRNA‐seq. (A) t‐SNE visualization of cells from paired primary tumours and peritoneal metastases of two patients. (B) Distribution of the ten epithelial clusters in Pri and Meta samples, shown separately. (C) Relative proportions of the ten epithelial clusters in Pri and Meta samples. (D) Pseudotime analysis of epithelial cells from metastases. Left: cells ordered along the inferred trajectory from early (dark) to late (light); the black line indicates the main lineage with bifurcation. Right: same embedding coloured by clusters (0–9). (E) Dot plot showing representative gene expression across the ten clusters; dot size indicates the fraction of expressing cells, and colour denotes average expression. (F) KEGG enrichment of clusters 0, 2, 4 and 6 based on cluster‐specific marker genes. (G) Representative TMA cores stained for SAA1 (green) and nuclei (blue). Scale bar, 200 µm. Quantification of SAA1 + cell percentage in Pri and Meta TMA cores is shown as violin plots with overlaid box plots (Pri, n = 81; Meta, n = 93). p value was determined by the Wilcoxon rank‐sum test, p = 2.9 × 10 − 1 6 . (H) t‐SNE plots showing SAA1 expression in primary (pri) and metastatic (meta) ovarian cancer cells. (I) Kaplan–Meier survival curves in the TCGA‐OV cohort ( n = 429) according to SAA1 expression (log‐rank p = 0.0075). (J) Multivariate Cox regression forest plot identifying independent prognostic factors for ovarian cancer, including SAA1 expression and clinicopathological variables.

    Article Snippet: Recombinant human SAA1 (ABclonal) and CXCL1 (Novoprotein, C597) were reconstituted in PBS containing 0.1% BSA.

    Techniques: Gene Expression, Expressing, Marker, Staining

    Tumour‐derived SAA1 does not directly promote tumour cell proliferation or migration but drives epithelial–macrophage crosstalk. (A) Colony formation assay after 14 days of culture comparing SKOV3 Cas9 WT vs. SKOV3 SAA1–/– and OVCAR3 Cas9 WT versus OVCAR3 SAA1–/– . (B) EdU staining of WT and SAA1‐KO ovarian cancer cells (SKOV3 and OVCAR3). Representative images showing Hoechst‐labelled nuclei (blue) and EdU‐positive proliferating cells (green). Scale bar, 20 µm. (C) Wound‐healing assays of WT and SAA1‐KO ovarian cancer cells (SKOV3 and OVCAR3). Representative images at 0, 24 and 48 h with quantification of relative migration rate. Scale bar, 100 µm. (D) Subcutaneous tumour growth of WT and SAA1‐KO SKOV3 cells in BALB/c nude mice. Representative tumours and growth curves showing no significant difference (ns). Data represent mean ± SD ( n = 4). (E) Overall cell–cell interaction network showing communication strength among major cell types in primary ovarian tumours. (F) CellChat analysis of SAA pathway activity in primary HGSOC. (G) Ligand–receptor interactions of SAA1 signalling between epithelial cells and macrophage subsets. (H) Comparison of EMT state composition between primary (pri) and metastatic (meta) tumours. Quantitative data are shown as mean ± SD. Statistical significance in A–C was assessed using unpaired two‐tailed Student’s t ‐test for the indicated comparisons; tumor growth curves in D were analyzed by two‐way ANOVA. ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Journal: Clinical and Translational Medicine

    Article Title: Tumour‐derived SAA1 reprogrammes macrophages to promote CXCL1‐mediated metastasis in Ovarian Cancer

    doi: 10.1002/ctm2.70698

    Figure Lengend Snippet: Tumour‐derived SAA1 does not directly promote tumour cell proliferation or migration but drives epithelial–macrophage crosstalk. (A) Colony formation assay after 14 days of culture comparing SKOV3 Cas9 WT vs. SKOV3 SAA1–/– and OVCAR3 Cas9 WT versus OVCAR3 SAA1–/– . (B) EdU staining of WT and SAA1‐KO ovarian cancer cells (SKOV3 and OVCAR3). Representative images showing Hoechst‐labelled nuclei (blue) and EdU‐positive proliferating cells (green). Scale bar, 20 µm. (C) Wound‐healing assays of WT and SAA1‐KO ovarian cancer cells (SKOV3 and OVCAR3). Representative images at 0, 24 and 48 h with quantification of relative migration rate. Scale bar, 100 µm. (D) Subcutaneous tumour growth of WT and SAA1‐KO SKOV3 cells in BALB/c nude mice. Representative tumours and growth curves showing no significant difference (ns). Data represent mean ± SD ( n = 4). (E) Overall cell–cell interaction network showing communication strength among major cell types in primary ovarian tumours. (F) CellChat analysis of SAA pathway activity in primary HGSOC. (G) Ligand–receptor interactions of SAA1 signalling between epithelial cells and macrophage subsets. (H) Comparison of EMT state composition between primary (pri) and metastatic (meta) tumours. Quantitative data are shown as mean ± SD. Statistical significance in A–C was assessed using unpaired two‐tailed Student’s t ‐test for the indicated comparisons; tumor growth curves in D were analyzed by two‐way ANOVA. ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Article Snippet: Recombinant human SAA1 (ABclonal) and CXCL1 (Novoprotein, C597) were reconstituted in PBS containing 0.1% BSA.

    Techniques: Derivative Assay, Migration, Colony Assay, Staining, Activity Assay, Comparison, Two Tailed Test

    Tumour‐derived SAA1 promotes macrophage‐mediated tumour cell migration and EMT through the SAA1–FPR2 axis. (A) Schematic of the indirect Transwell co‐culture system, with ovarian cancer cells (SKOV3 or OVCAR3; WT or SAA1–/–) seeded in the upper inserts and macrophages (Mø) in the lower chambers. (B) Transwell migration of OVCAR3 and SKOV3 cells with or without macrophages, with representative images and quantification of relative migration rates, n = 3. Scale bar, 50 µm. (C) Migration assays of SKOV3 Cas9 WT and SKOV3 SAA1–/– cells co‐cultured with macrophages under different conditions, n = 3. Representative images (left) and quantification (right). Scale bar, 50 µm. (D) Schematic of a three‐stage cascade co‐culture model: (i) tumour‐conditioned medium (TCM) from WT or SAA1–/– SKOV3 cells; (ii) macrophages exposed to TCM for 24 h to generate tumour‐educated macrophage conditioned medium (TeMCM); (iii) TeMCM applied to ovarian cancer organoids/tumour cells. (E) CMFDA‐stained ovarian cancer organoids cultured with TeMCM from WT or KO SKOV3 cells, n = 3. Scale bar, 100 µm. (F) Ovarian cancer organoids cultured under indicated conditions, stained for E‐cadherin (green), vimentin (cyan), pan‐CK (magenta), and nuclei (blue). CMFDA and H&E staining show viability and morphology. Scale bar, 100 µm. (G) Immunofluorescence of SKOV3 cells treated with TeMCM, stained for nuclei (blue), E‐cadherin (green), and vimentin (red). Scale bar, 10 µm. (H) Quantification of fluorescence intensity in G. (I) Western blot analysis of E‐cadherin and vimentin in SKOV3 cells under different MCM or TeMCM treatments. Quantitative data in B, C and H are shown as mean ± SD ( n = 3 independent experiments). Statistical significance was determined by Student's t ‐test in B and by one‐way ANOVA with multiple comparisons test in C and H. ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Journal: Clinical and Translational Medicine

    Article Title: Tumour‐derived SAA1 reprogrammes macrophages to promote CXCL1‐mediated metastasis in Ovarian Cancer

    doi: 10.1002/ctm2.70698

    Figure Lengend Snippet: Tumour‐derived SAA1 promotes macrophage‐mediated tumour cell migration and EMT through the SAA1–FPR2 axis. (A) Schematic of the indirect Transwell co‐culture system, with ovarian cancer cells (SKOV3 or OVCAR3; WT or SAA1–/–) seeded in the upper inserts and macrophages (Mø) in the lower chambers. (B) Transwell migration of OVCAR3 and SKOV3 cells with or without macrophages, with representative images and quantification of relative migration rates, n = 3. Scale bar, 50 µm. (C) Migration assays of SKOV3 Cas9 WT and SKOV3 SAA1–/– cells co‐cultured with macrophages under different conditions, n = 3. Representative images (left) and quantification (right). Scale bar, 50 µm. (D) Schematic of a three‐stage cascade co‐culture model: (i) tumour‐conditioned medium (TCM) from WT or SAA1–/– SKOV3 cells; (ii) macrophages exposed to TCM for 24 h to generate tumour‐educated macrophage conditioned medium (TeMCM); (iii) TeMCM applied to ovarian cancer organoids/tumour cells. (E) CMFDA‐stained ovarian cancer organoids cultured with TeMCM from WT or KO SKOV3 cells, n = 3. Scale bar, 100 µm. (F) Ovarian cancer organoids cultured under indicated conditions, stained for E‐cadherin (green), vimentin (cyan), pan‐CK (magenta), and nuclei (blue). CMFDA and H&E staining show viability and morphology. Scale bar, 100 µm. (G) Immunofluorescence of SKOV3 cells treated with TeMCM, stained for nuclei (blue), E‐cadherin (green), and vimentin (red). Scale bar, 10 µm. (H) Quantification of fluorescence intensity in G. (I) Western blot analysis of E‐cadherin and vimentin in SKOV3 cells under different MCM or TeMCM treatments. Quantitative data in B, C and H are shown as mean ± SD ( n = 3 independent experiments). Statistical significance was determined by Student's t ‐test in B and by one‐way ANOVA with multiple comparisons test in C and H. ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Article Snippet: Recombinant human SAA1 (ABclonal) and CXCL1 (Novoprotein, C597) were reconstituted in PBS containing 0.1% BSA.

    Techniques: Derivative Assay, Migration, Co-Culture Assay, Cell Culture, Staining, Immunofluorescence, Fluorescence, Western Blot

    SAA1–FPR2 axis drives macrophage recruitment and polarization. (A) Macrophage migration under WTCM (SKOV3 Cas9 WT CM), KOCM (SKOV3 SAA1–/– CM), recombinant SAA1, and/or FPR2 inhibitor WRW4. Representative images (left) and quantification (right). Scale bar, 50 µm. (B) Representative tumour sections from two patients stained for Pan‐CK (red), SAA1 (green), CD68 (cyan), FPR2 (grey), and DAPI (blue), with merged images shown. Scale bar, 20 µm. (C) Representative images showing morphological changes in THP‐1–derived macrophages under the indicated culture conditions. Scale bar, 100 µm. (D) Immunofluorescence staining of THP‐1–derived macrophages under the indicated culture conditions. CD86 (green), CD206 (red), and nuclei (DAPI, blue). Scale bar, 10 µm. (E) Representative flow cytometry plots and quantification of CD206 + macrophages under different treatments, including control medium, recombinant SAA1, FPR2 antagonist WRW4, and conditioned media from SKOV3 Cas9 WT (WTCM) or SKOV3 SAA1–/– (KOCM), n = 3. (F) Multiplex immunofluorescence staining of SAA1 (green), CD68 (cyan), CD206 (red) and DAPI (blue) in ovarian cancer tissues. Scale bars, 300 µm. Quantitative data in A, D and E are shown as mean ± SD ( n = 3 independent experiments). Statistical significance was determined by one‐way ANOVA. ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Journal: Clinical and Translational Medicine

    Article Title: Tumour‐derived SAA1 reprogrammes macrophages to promote CXCL1‐mediated metastasis in Ovarian Cancer

    doi: 10.1002/ctm2.70698

    Figure Lengend Snippet: SAA1–FPR2 axis drives macrophage recruitment and polarization. (A) Macrophage migration under WTCM (SKOV3 Cas9 WT CM), KOCM (SKOV3 SAA1–/– CM), recombinant SAA1, and/or FPR2 inhibitor WRW4. Representative images (left) and quantification (right). Scale bar, 50 µm. (B) Representative tumour sections from two patients stained for Pan‐CK (red), SAA1 (green), CD68 (cyan), FPR2 (grey), and DAPI (blue), with merged images shown. Scale bar, 20 µm. (C) Representative images showing morphological changes in THP‐1–derived macrophages under the indicated culture conditions. Scale bar, 100 µm. (D) Immunofluorescence staining of THP‐1–derived macrophages under the indicated culture conditions. CD86 (green), CD206 (red), and nuclei (DAPI, blue). Scale bar, 10 µm. (E) Representative flow cytometry plots and quantification of CD206 + macrophages under different treatments, including control medium, recombinant SAA1, FPR2 antagonist WRW4, and conditioned media from SKOV3 Cas9 WT (WTCM) or SKOV3 SAA1–/– (KOCM), n = 3. (F) Multiplex immunofluorescence staining of SAA1 (green), CD68 (cyan), CD206 (red) and DAPI (blue) in ovarian cancer tissues. Scale bars, 300 µm. Quantitative data in A, D and E are shown as mean ± SD ( n = 3 independent experiments). Statistical significance was determined by one‐way ANOVA. ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Article Snippet: Recombinant human SAA1 (ABclonal) and CXCL1 (Novoprotein, C597) were reconstituted in PBS containing 0.1% BSA.

    Techniques: Migration, Recombinant, Staining, Derivative Assay, Immunofluorescence, Flow Cytometry, Control, Multiplex Assay

    SAA1–FPR2 axis drives CXCL1 production in macrophages via JAK2–STAT3 signalling. (A) Proteomic profiling of secreted factors in TeMCM generated with TCM from SKOV3 Cas9 WT versus SKOV3 SAA1–/– cells. (B) KEGG pathway enrichment (bubble plot) of DEGs from macrophages exposed to SKOV3 Cas9 WT versus SKOV3 SAA1–/– TCM. (C) Heatmap of cytokine/chemokine‐related DEGs from RNA‐seq of macrophages educated with SKOV3 Cas9 WT TCM (A1–A3) or SKOV3 SAA1–/– TCM (B4–B6). (D) Venn diagram showing overlap of upregulated genes from RNA‐seq and proteomics. The 38 shared genes are listed below. (E) Differential expression of the 38 overlapping genes. (F) CXCL1 expression in macrophages under different treatments. Upper: densitometric quantification; lower: representative immunoblots. (G) ELISA quantification of CXCL1 in macrophage supernatants under indicated treatments, n = 3. (H) Predicted STAT3‐binding sites within the CXCL1 promoter (−2000 bp to TSS) are shown, along with the consensus STAT3 motif. (I) ChIP–qPCR showing STAT3 enrichment at nine predicted binding sites on the CXCL1 promoter in macrophages treated with SKOV3 Cas9 WT TCM, SKOV3 SAA1–/– TCM, or SKOV3 SAA1–/– TCM + rSAA1. (J) Dual‐luciferase assay of CXCL1 promoter activity upon STAT3 overexpression, n = 3. Reporter groups: empty vector, CXCL1 WT promoter, STAT3 + WT, and STAT3 + MUT. (K) Immunoblot of p‐JAK2, JAK2, p‐STAT3, STAT3, and CXCL1 in macrophages treated with SKOV3 Cas9 WT or SKOV3 SAA1–/– TCM with or without WRW4, rSAA1, Fedratinib, or Stattic. Quantitative data in F, G, I and K are shown as mean ± SD ( n = 3 independent experiments). Statistical significance was determined by one‐way ANOVA. ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Journal: Clinical and Translational Medicine

    Article Title: Tumour‐derived SAA1 reprogrammes macrophages to promote CXCL1‐mediated metastasis in Ovarian Cancer

    doi: 10.1002/ctm2.70698

    Figure Lengend Snippet: SAA1–FPR2 axis drives CXCL1 production in macrophages via JAK2–STAT3 signalling. (A) Proteomic profiling of secreted factors in TeMCM generated with TCM from SKOV3 Cas9 WT versus SKOV3 SAA1–/– cells. (B) KEGG pathway enrichment (bubble plot) of DEGs from macrophages exposed to SKOV3 Cas9 WT versus SKOV3 SAA1–/– TCM. (C) Heatmap of cytokine/chemokine‐related DEGs from RNA‐seq of macrophages educated with SKOV3 Cas9 WT TCM (A1–A3) or SKOV3 SAA1–/– TCM (B4–B6). (D) Venn diagram showing overlap of upregulated genes from RNA‐seq and proteomics. The 38 shared genes are listed below. (E) Differential expression of the 38 overlapping genes. (F) CXCL1 expression in macrophages under different treatments. Upper: densitometric quantification; lower: representative immunoblots. (G) ELISA quantification of CXCL1 in macrophage supernatants under indicated treatments, n = 3. (H) Predicted STAT3‐binding sites within the CXCL1 promoter (−2000 bp to TSS) are shown, along with the consensus STAT3 motif. (I) ChIP–qPCR showing STAT3 enrichment at nine predicted binding sites on the CXCL1 promoter in macrophages treated with SKOV3 Cas9 WT TCM, SKOV3 SAA1–/– TCM, or SKOV3 SAA1–/– TCM + rSAA1. (J) Dual‐luciferase assay of CXCL1 promoter activity upon STAT3 overexpression, n = 3. Reporter groups: empty vector, CXCL1 WT promoter, STAT3 + WT, and STAT3 + MUT. (K) Immunoblot of p‐JAK2, JAK2, p‐STAT3, STAT3, and CXCL1 in macrophages treated with SKOV3 Cas9 WT or SKOV3 SAA1–/– TCM with or without WRW4, rSAA1, Fedratinib, or Stattic. Quantitative data in F, G, I and K are shown as mean ± SD ( n = 3 independent experiments). Statistical significance was determined by one‐way ANOVA. ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Article Snippet: Recombinant human SAA1 (ABclonal) and CXCL1 (Novoprotein, C597) were reconstituted in PBS containing 0.1% BSA.

    Techniques: Generated, RNA Sequencing, Quantitative Proteomics, Expressing, Western Blot, Enzyme-linked Immunosorbent Assay, Binding Assay, ChIP-qPCR, Luciferase, Activity Assay, Over Expression, Plasmid Preparation

    CXCL1 enhances the invasive and metastatic potential of ovarian cancer cells. (A–B) Wound‐healing assays of SKOV3 Cas9 WT and SKOV3 SAA1–/– cells treated with rCXCL1 or PBS, n = 3. Representative images (left) and quantification of migration rate (right). Scale bar, 100 µm. (C) Transwell migration of SKOV3 Cas9 WT and SKOV3 SAA1–/– cells treated with rCXCL1 or PBS, n = 3. Representative images (left) and quantification (right). Scale bar, 50 µm. (D) Matrigel invasion assay of SKOV3 Cas9 WT and SKOV3 SAA1–/– cells with rCXCL1 or PBS, n = 3. Representative images (left) and quantification (right). Scale bar, 50 µm. (E) Left: schematic illustration of the inverse invasion model; middle: laser‐induced fluorescence imaging; right: quantitative analysis of the effect of CXCL1 on SKOV3‐GFP invasion. (F) Representative three‐dimensional reconstruction based on Z‐stack scanning, presented as a depth‐coded heatmap. (G) Immunoblot of E‐cadherin and vimentin in SKOV3 Cas9 WT and SKOV3 SAA1–/– cells treated with PBS or rCXCL1. (H) Immunoblot of E‐cadherin, β‐catenin, and vimentin in SKOV3 cells treated with increasing concentrations of rCXCL1 (0–100 ng/mL, 24 h). (I) Representative tissue microarray (TMA) cores stained for CXCL1 by immunohistochemistry. Scale bar, 2 mm. Kaplan–Meier overall survival analysis of the same cohort stratified by CXCL1 IHC score (High vs Low). Log‐rank p = 0.029. (J) Kaplan–Meier analysis of TCGA‐OV cohort stratified by CXCL1 mRNA expression (High vs Low). Log‐rank p = 0.0083; HR = 1.60, 95% CI 1.13–2.27. Quantitative data in A–E are shown as mean ± SD ( n = 3 independent experiments). Statistical significance was determined by Student's t ‐test in A–D and by one‐way ANOVA in E. ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Journal: Clinical and Translational Medicine

    Article Title: Tumour‐derived SAA1 reprogrammes macrophages to promote CXCL1‐mediated metastasis in Ovarian Cancer

    doi: 10.1002/ctm2.70698

    Figure Lengend Snippet: CXCL1 enhances the invasive and metastatic potential of ovarian cancer cells. (A–B) Wound‐healing assays of SKOV3 Cas9 WT and SKOV3 SAA1–/– cells treated with rCXCL1 or PBS, n = 3. Representative images (left) and quantification of migration rate (right). Scale bar, 100 µm. (C) Transwell migration of SKOV3 Cas9 WT and SKOV3 SAA1–/– cells treated with rCXCL1 or PBS, n = 3. Representative images (left) and quantification (right). Scale bar, 50 µm. (D) Matrigel invasion assay of SKOV3 Cas9 WT and SKOV3 SAA1–/– cells with rCXCL1 or PBS, n = 3. Representative images (left) and quantification (right). Scale bar, 50 µm. (E) Left: schematic illustration of the inverse invasion model; middle: laser‐induced fluorescence imaging; right: quantitative analysis of the effect of CXCL1 on SKOV3‐GFP invasion. (F) Representative three‐dimensional reconstruction based on Z‐stack scanning, presented as a depth‐coded heatmap. (G) Immunoblot of E‐cadherin and vimentin in SKOV3 Cas9 WT and SKOV3 SAA1–/– cells treated with PBS or rCXCL1. (H) Immunoblot of E‐cadherin, β‐catenin, and vimentin in SKOV3 cells treated with increasing concentrations of rCXCL1 (0–100 ng/mL, 24 h). (I) Representative tissue microarray (TMA) cores stained for CXCL1 by immunohistochemistry. Scale bar, 2 mm. Kaplan–Meier overall survival analysis of the same cohort stratified by CXCL1 IHC score (High vs Low). Log‐rank p = 0.029. (J) Kaplan–Meier analysis of TCGA‐OV cohort stratified by CXCL1 mRNA expression (High vs Low). Log‐rank p = 0.0083; HR = 1.60, 95% CI 1.13–2.27. Quantitative data in A–E are shown as mean ± SD ( n = 3 independent experiments). Statistical significance was determined by Student's t ‐test in A–D and by one‐way ANOVA in E. ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Article Snippet: Recombinant human SAA1 (ABclonal) and CXCL1 (Novoprotein, C597) were reconstituted in PBS containing 0.1% BSA.

    Techniques: Migration, Invasion Assay, Fluorescence, Imaging, Western Blot, Microarray, Staining, Immunohistochemistry, Expressing

    Inhibition of the SAA1–TAM–CXCL1 axis suppresses ovarian cancer metastasis. (A) Experimental scheme for the C57BL/6 mouse model of ovarian cancer peritoneal dissemination. (B) Western blot of SAA1 in luciferase‐labelled ID8 cells. Protein levels were compared between shSAA1‐ID8‐LUC and shCtrl‐ID8‐LUC. (C) Bioluminescence imaging at Week 7 after intraperitoneal injection of ID8‐LUC or shSAA1‐ID8‐LUC cells, treated with control liposomes (Ctrl Lip), clodronate liposomes (CLO Lip), vehicle (DMSO), or the CXCL1 receptor inhibitor SB225002, n = 4. (D) Quantification of average luminescence intensity. (E) Immunohistochemistry of F4/80 in spleen sections from mice bearing shCtrl‐ID8‐LUC or shSAA1‐ID8‐LUC tumours, with or without Ctrl Lip, CLO Lip, DMSO, or SB225002. Left: representative fields from red pulp; right: quantification of F4/80 + area ratio (%). Scale bar, 100 µm. (F) Multiplex immunofluorescence of peritoneal tumour sections under the indicated interventions. Staining includes Pan‐CK (red), SAA1 (green), F4/80 (cyan), CD206 (magenta), CXCL1 (grey), and nuclei (blue). Merged images are shown in the bottom row. Scale bar, 20 µm. Quantitative data in D–F are shown as mean ± SD. Statistical significance was determined by one‐way ANOVA. ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Journal: Clinical and Translational Medicine

    Article Title: Tumour‐derived SAA1 reprogrammes macrophages to promote CXCL1‐mediated metastasis in Ovarian Cancer

    doi: 10.1002/ctm2.70698

    Figure Lengend Snippet: Inhibition of the SAA1–TAM–CXCL1 axis suppresses ovarian cancer metastasis. (A) Experimental scheme for the C57BL/6 mouse model of ovarian cancer peritoneal dissemination. (B) Western blot of SAA1 in luciferase‐labelled ID8 cells. Protein levels were compared between shSAA1‐ID8‐LUC and shCtrl‐ID8‐LUC. (C) Bioluminescence imaging at Week 7 after intraperitoneal injection of ID8‐LUC or shSAA1‐ID8‐LUC cells, treated with control liposomes (Ctrl Lip), clodronate liposomes (CLO Lip), vehicle (DMSO), or the CXCL1 receptor inhibitor SB225002, n = 4. (D) Quantification of average luminescence intensity. (E) Immunohistochemistry of F4/80 in spleen sections from mice bearing shCtrl‐ID8‐LUC or shSAA1‐ID8‐LUC tumours, with or without Ctrl Lip, CLO Lip, DMSO, or SB225002. Left: representative fields from red pulp; right: quantification of F4/80 + area ratio (%). Scale bar, 100 µm. (F) Multiplex immunofluorescence of peritoneal tumour sections under the indicated interventions. Staining includes Pan‐CK (red), SAA1 (green), F4/80 (cyan), CD206 (magenta), CXCL1 (grey), and nuclei (blue). Merged images are shown in the bottom row. Scale bar, 20 µm. Quantitative data in D–F are shown as mean ± SD. Statistical significance was determined by one‐way ANOVA. ns, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

    Article Snippet: Recombinant human SAA1 (ABclonal) and CXCL1 (Novoprotein, C597) were reconstituted in PBS containing 0.1% BSA.

    Techniques: Inhibition, Western Blot, Luciferase, Imaging, Injection, Control, Liposomes, Immunohistochemistry, Multiplex Assay, Immunofluorescence, Staining

    Enhanced SAA1 expression and NET formation in plasma of MS patients. (A) SAA1 protein expression was quantified by ELISA in plasma samples collected from MS patients and HC. (B) H3.1-nucleosome expression was quantified by ELISA in plasma samples collected from MS patients and HC

    Journal: Journal of Neuroinflammation

    Article Title: Single-cell RNA sequencing uncovers neutrophil clusters associated with autoimmune neuroinflammation

    doi: 10.1186/s12974-026-03772-9

    Figure Lengend Snippet: Enhanced SAA1 expression and NET formation in plasma of MS patients. (A) SAA1 protein expression was quantified by ELISA in plasma samples collected from MS patients and HC. (B) H3.1-nucleosome expression was quantified by ELISA in plasma samples collected from MS patients and HC

    Article Snippet: The human SAA1 ELISA kit (DY3019-05; R & D Systems, Minneapolis, MN) detected human SAA1 in plasma samples from MS patients and HC.

    Techniques: Expressing, Clinical Proteomics, Enzyme-linked Immunosorbent Assay

    a , b Schematic diagram showing serum cytokine microarray analysis of continuous P2’s serum samples before (PS1 and PS2) or after (PS3, flare; PS4 and PS5, non-flare) the onset of recurrent fever ( a ). PCA analysis of sample variance determined by semi-quantitative 174 cytokines antibody array on serum samples of C1-C3 from three unaffected controls and PS1-PS5 from P2 ( b ). c–e The integrated relative MFI plots of P2’s serum cytokine levels. 26 cytokines peaked in PS3 were enrich in group 1 (left), 24 cytokines higher than control were enriched in group 2 (right) ( c ). The relative MFI was calculated by normalizing the average MFI of the unaffected controls ( n = 3) to 0, and setting the largest MFI to 1 or the smallest MFI to −1 across 5 samples from P2. Boxplots exhibiting expression scores of cytokines of group 1 ( d ) and group 2 ( e ) in indicated cell with Seurat AddModuleScore function. The cell number of each subtype (listed in the “Methods” section), was employed for p value calculations. Boxes show the median (center line), 25th and 75th percentiles (upper and lower hinges), and whiskers extend to 1.5× the interquartile range, representing the maximum and minimum values. f Average expression values (arcsinh transformed) of cl. Casp-3 across identified peripheral immune cell lineages in PBMCs freshly isolated from four unaffected controls (C) and two patients (P, 1 sample from P1 and 2 samples from P2) by mass cytometry by time-of-flight (CyTOF) analysis. g–j Representative contour plots of cl. Casp-3 ( g , h ) and histograms of total RIPK1, pRIPK1(S166) levels ( i , j ) in CD4 + T and CD8 + T cells in freshly isolated PBMCs from unaffected controls (for cl. Casp-3, n = 12; for pRIPK1(S166), n = 10) and patients ( n = 4 for P1 and P2) (left). Summary histograms of cl. Casp-3 and pRIPK1(S166) (right) were shown. k Representative histogram and statistical analysis of surface CD69 expression on CD3 + T cells from unaffected controls ( n = 7) and two patients ( n = 3 for P1 and P2). l Serum IFNγ, sCD25, sCD95 and CD95L of unaffected controls (for IFNγ, n = 9; for sCD25, n = 15; for sCD95 and CD95L, n = 10), two patients (for IFNγ, P1, n = 5, P2 = 6; for sCD25, P1, n = 5, P2, n = 4; for sCD95, P1 and P2, n = 7; for CD95L, P1 = 7; P2 = 8) and their parents (for IFNγ and sCD25, n = 7; for sCD95 and CD95L, n = 6) as well as two CRIA syndrome patients ( n = 6) determined by ELISA. T denotes 10 ng ml -1 TNF; S denotes 250 nM SM164; Z denotes 25 μM z-VAD-fmk. All histogram graphs show mean ± SD. P values were determined by two-tailed unpaired t-test. Data in g–k were pooled from two independent experiments.

    Journal: Nature Communications

    Article Title: CD8 + T cell loss induces autoinflammation in inborn errors of cell death

    doi: 10.1038/s41467-026-70317-2

    Figure Lengend Snippet: a , b Schematic diagram showing serum cytokine microarray analysis of continuous P2’s serum samples before (PS1 and PS2) or after (PS3, flare; PS4 and PS5, non-flare) the onset of recurrent fever ( a ). PCA analysis of sample variance determined by semi-quantitative 174 cytokines antibody array on serum samples of C1-C3 from three unaffected controls and PS1-PS5 from P2 ( b ). c–e The integrated relative MFI plots of P2’s serum cytokine levels. 26 cytokines peaked in PS3 were enrich in group 1 (left), 24 cytokines higher than control were enriched in group 2 (right) ( c ). The relative MFI was calculated by normalizing the average MFI of the unaffected controls ( n = 3) to 0, and setting the largest MFI to 1 or the smallest MFI to −1 across 5 samples from P2. Boxplots exhibiting expression scores of cytokines of group 1 ( d ) and group 2 ( e ) in indicated cell with Seurat AddModuleScore function. The cell number of each subtype (listed in the “Methods” section), was employed for p value calculations. Boxes show the median (center line), 25th and 75th percentiles (upper and lower hinges), and whiskers extend to 1.5× the interquartile range, representing the maximum and minimum values. f Average expression values (arcsinh transformed) of cl. Casp-3 across identified peripheral immune cell lineages in PBMCs freshly isolated from four unaffected controls (C) and two patients (P, 1 sample from P1 and 2 samples from P2) by mass cytometry by time-of-flight (CyTOF) analysis. g–j Representative contour plots of cl. Casp-3 ( g , h ) and histograms of total RIPK1, pRIPK1(S166) levels ( i , j ) in CD4 + T and CD8 + T cells in freshly isolated PBMCs from unaffected controls (for cl. Casp-3, n = 12; for pRIPK1(S166), n = 10) and patients ( n = 4 for P1 and P2) (left). Summary histograms of cl. Casp-3 and pRIPK1(S166) (right) were shown. k Representative histogram and statistical analysis of surface CD69 expression on CD3 + T cells from unaffected controls ( n = 7) and two patients ( n = 3 for P1 and P2). l Serum IFNγ, sCD25, sCD95 and CD95L of unaffected controls (for IFNγ, n = 9; for sCD25, n = 15; for sCD95 and CD95L, n = 10), two patients (for IFNγ, P1, n = 5, P2 = 6; for sCD25, P1, n = 5, P2, n = 4; for sCD95, P1 and P2, n = 7; for CD95L, P1 = 7; P2 = 8) and their parents (for IFNγ and sCD25, n = 7; for sCD95 and CD95L, n = 6) as well as two CRIA syndrome patients ( n = 6) determined by ELISA. T denotes 10 ng ml -1 TNF; S denotes 250 nM SM164; Z denotes 25 μM z-VAD-fmk. All histogram graphs show mean ± SD. P values were determined by two-tailed unpaired t-test. Data in g–k were pooled from two independent experiments.

    Article Snippet: Human or mouse serum cytokines were measured by enzyme-linked immunosorbent assay (ELISA) (Multi Sciences: 70-EK1280, 70-EK194, 70-EK182HS, 70-EK106HS, 70-EK191, 70-EK180HS, 70-EK1F01, 70-EK1F02, EK206HS, EK282HS/2) according to the manufacturer’s instructions.

    Techniques: Microarray, Ab Array, Control, Expressing, Transformation Assay, Isolation, Mass Cytometry, Enzyme-linked Immunosorbent Assay, Two Tailed Test

    a Schematic diagram of T cell-MDM co-culture system. b , c qRT-PCR analysis of TNF, IL1B and IL6 mRNA levels in GM-CSF-activated monocytes derived macrophages (MDMs) co-cultured with or without T cells for 6 h. GM-CSF-activated MDMs generated from ( b , left) unaffected control 1 (C1) or ( b , right) unaffected control 3 (C3) or P1 ( c ) were co-cultured with donor-matched T cells as well as T cells from other unaffected controls (C2 and C4) or patients as indicated. d Dot plot of IFNG, TNF in cell subtypes found in scRNA-seq of PBMCs from three unaffected controls and two patients. e Representative histograms and statistical analysis of TNF and IFNγ expression in CD8 + T cells in PBMCs isolated from unaffected controls ( n = 6) and patients ( n = 3 from P1 and P2) treated with 10 ng ml -1 TNF (T) with or without 250 nM SM-164 (S), 25 μM z-VAD-fmk (Z) for 24 h. f , T cells isolated from P2 were co-cultured with MDMs generated from unaffected control in the presence of 10 μg ml -1 adalimumab, 10 μg ml -1 emapalumab alone or in combination for 6 h. TNF, IL1B and IL6 mRNA levels of MDMs were analyzed by qRT-PCR. g Experimental timeline for generation of lineage negative bone marrow cells (Lin - BMs)-transplanted mice with conditional overexpression of human WT or mutated RIPK1 K377E or R390G in CD8 + T cell- or myeloid cell-specific lineage. h, i ELISA measurement of serum Tnf and Il6 levels in mice specifically overexpressing WT or mutated hRIPK1 in ( h ) CD8 + T cells (EV, n = 5; WT, K377E and R390G n = 7) or ( i ) myeloid cells (EV, n = 5; WT, K377E and R390G n = 6). All histogram graphs show mean ± SD. P values were determined by one-way ANOVA with Tukey’s multiple comparisons test. Data in b , c , and f show the means ± SD of technical triplicates. The results shown in b were derived from two independent experiments using cells from different donors. The experiment in ( c , h , i , f ) is representative of two independent experiments. Data in e were pooled from two independent experiments.

    Journal: Nature Communications

    Article Title: CD8 + T cell loss induces autoinflammation in inborn errors of cell death

    doi: 10.1038/s41467-026-70317-2

    Figure Lengend Snippet: a Schematic diagram of T cell-MDM co-culture system. b , c qRT-PCR analysis of TNF, IL1B and IL6 mRNA levels in GM-CSF-activated monocytes derived macrophages (MDMs) co-cultured with or without T cells for 6 h. GM-CSF-activated MDMs generated from ( b , left) unaffected control 1 (C1) or ( b , right) unaffected control 3 (C3) or P1 ( c ) were co-cultured with donor-matched T cells as well as T cells from other unaffected controls (C2 and C4) or patients as indicated. d Dot plot of IFNG, TNF in cell subtypes found in scRNA-seq of PBMCs from three unaffected controls and two patients. e Representative histograms and statistical analysis of TNF and IFNγ expression in CD8 + T cells in PBMCs isolated from unaffected controls ( n = 6) and patients ( n = 3 from P1 and P2) treated with 10 ng ml -1 TNF (T) with or without 250 nM SM-164 (S), 25 μM z-VAD-fmk (Z) for 24 h. f , T cells isolated from P2 were co-cultured with MDMs generated from unaffected control in the presence of 10 μg ml -1 adalimumab, 10 μg ml -1 emapalumab alone or in combination for 6 h. TNF, IL1B and IL6 mRNA levels of MDMs were analyzed by qRT-PCR. g Experimental timeline for generation of lineage negative bone marrow cells (Lin - BMs)-transplanted mice with conditional overexpression of human WT or mutated RIPK1 K377E or R390G in CD8 + T cell- or myeloid cell-specific lineage. h, i ELISA measurement of serum Tnf and Il6 levels in mice specifically overexpressing WT or mutated hRIPK1 in ( h ) CD8 + T cells (EV, n = 5; WT, K377E and R390G n = 7) or ( i ) myeloid cells (EV, n = 5; WT, K377E and R390G n = 6). All histogram graphs show mean ± SD. P values were determined by one-way ANOVA with Tukey’s multiple comparisons test. Data in b , c , and f show the means ± SD of technical triplicates. The results shown in b were derived from two independent experiments using cells from different donors. The experiment in ( c , h , i , f ) is representative of two independent experiments. Data in e were pooled from two independent experiments.

    Article Snippet: Human or mouse serum cytokines were measured by enzyme-linked immunosorbent assay (ELISA) (Multi Sciences: 70-EK1280, 70-EK194, 70-EK182HS, 70-EK106HS, 70-EK191, 70-EK180HS, 70-EK1F01, 70-EK1F02, EK206HS, EK282HS/2) according to the manufacturer’s instructions.

    Techniques: Co-Culture Assay, Quantitative RT-PCR, Derivative Assay, Cell Culture, Generated, Control, Expressing, Isolation, Over Expression, Enzyme-linked Immunosorbent Assay

    Verification of potential biomarkers for AS. (A) Expression levels of SAA1, FERMT3, ILK, and TLN1 in plasma samples from active-stage AS patients, stable-stage AS patients, and healthy controls measured by proteomics. ROC curves for the individual protein (SAA1, FERMT3, ILK, and TLN1) as a predictor to classify AS patients from healthy controls (B), and active-stage AS patients from stable-stage AS patients (C). (D) ELISA analysis of SAA1, FERMT3, ILK, and TLN1 expressions in the plasma samples from an independent validation cohort of healthy controls (N, n = 24), active-stage AS (A, n = 27), and stable-stage AS patients (S, n = 28). Statistical analyses employed Wilcoxon rank-sum test for intergroup comparisons, with results reported as mean ± SEM. Significance thresholds based on BH-adjusted p -values were defined as: *, <0.05; **, <0.01; ***, <0.001.

    Journal: Journal of Advanced Research

    Article Title: Characterization of immune features and discovery of potential biomarkers for ankylosing spondylitis using deep plasma proteomics

    doi: 10.1016/j.jare.2025.05.052

    Figure Lengend Snippet: Verification of potential biomarkers for AS. (A) Expression levels of SAA1, FERMT3, ILK, and TLN1 in plasma samples from active-stage AS patients, stable-stage AS patients, and healthy controls measured by proteomics. ROC curves for the individual protein (SAA1, FERMT3, ILK, and TLN1) as a predictor to classify AS patients from healthy controls (B), and active-stage AS patients from stable-stage AS patients (C). (D) ELISA analysis of SAA1, FERMT3, ILK, and TLN1 expressions in the plasma samples from an independent validation cohort of healthy controls (N, n = 24), active-stage AS (A, n = 27), and stable-stage AS patients (S, n = 28). Statistical analyses employed Wilcoxon rank-sum test for intergroup comparisons, with results reported as mean ± SEM. Significance thresholds based on BH-adjusted p -values were defined as: *, <0.05; **, <0.01; ***, <0.001.

    Article Snippet: The human serum amyloid A (SAA1) ELISA kit (#OKIA00083) was purchased from Aviva Systems Biology Company (San Diego, CA, USA).

    Techniques: Expressing, Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Biomarker Discovery

    (A) Cell-cell communication analysis of SAA signaling pathway for the indicated depots and cells. Line colors and widths represent the sending cell and the strength of the signal, respectively. (B) Pseudobulk comparison of differentially expressed genes in epiploic vs. subcutaneous depots, highlighting the indicated signaling pathways. (C) Expression of SAA1 mRNA upon stimulation with LPS (10 ng/mL), TNF-α (2.5 ng/mL), IL-1β (10 ng/mL), or IL-6 (10 ng/mL) for 24 h. Data are presented as fold change (FC) over vehicle. Significant (<0.05) p values compared with the vehicle from one-way ANOVA are shown. (D) Relative expression of SAA1 (left) and SAA2 (right) mRNA in adipocytes, ASPCs, adipose-derived endothelial cells (adECs), and THP1-derived macrophages (THP1 M0). Significant (<0.05) p values compared with the cell-type-specific control from one-way ANOVA are shown. (E) Results from ELISA measurements of SAA in conditioned media from human adipocytes incubated without or with LPS for 72 h. Results are displayed as mean, error bars represent standard error of the mean, and statistical significance was calculated using Student’s t test. (F) Analyses of DNA methylation in the indicated cell classes for the promoter and gene body regions of SAA1 and SAA2 , respectively. Chromosomal localization and motifs for NFKB2/RELA/REL and STAT3 are indicated for both genes. (G) SAA1 and SAA2 mRNA expression in adipocytes treated with or without LPS in the presence or absence of different inhibitors described in the main text. Data are presented as FC over vehicle. Significant (<0.05) p values compared with the vehicle from one-way ANOVA are shown. For (C), (D), and (G), data are displayed as geometric mean ± 95% confidence intervals with technical replicates displayed from three independent experiments. ASPC, adipose stromal and progenitor cell.

    Journal: Cell metabolism

    Article Title: Cytoarchitectural multi-depot profiling reveals immune-metabolic crosstalk in human colon-associated adipose tissue

    doi: 10.1016/j.cmet.2025.12.008

    Figure Lengend Snippet: (A) Cell-cell communication analysis of SAA signaling pathway for the indicated depots and cells. Line colors and widths represent the sending cell and the strength of the signal, respectively. (B) Pseudobulk comparison of differentially expressed genes in epiploic vs. subcutaneous depots, highlighting the indicated signaling pathways. (C) Expression of SAA1 mRNA upon stimulation with LPS (10 ng/mL), TNF-α (2.5 ng/mL), IL-1β (10 ng/mL), or IL-6 (10 ng/mL) for 24 h. Data are presented as fold change (FC) over vehicle. Significant (<0.05) p values compared with the vehicle from one-way ANOVA are shown. (D) Relative expression of SAA1 (left) and SAA2 (right) mRNA in adipocytes, ASPCs, adipose-derived endothelial cells (adECs), and THP1-derived macrophages (THP1 M0). Significant (<0.05) p values compared with the cell-type-specific control from one-way ANOVA are shown. (E) Results from ELISA measurements of SAA in conditioned media from human adipocytes incubated without or with LPS for 72 h. Results are displayed as mean, error bars represent standard error of the mean, and statistical significance was calculated using Student’s t test. (F) Analyses of DNA methylation in the indicated cell classes for the promoter and gene body regions of SAA1 and SAA2 , respectively. Chromosomal localization and motifs for NFKB2/RELA/REL and STAT3 are indicated for both genes. (G) SAA1 and SAA2 mRNA expression in adipocytes treated with or without LPS in the presence or absence of different inhibitors described in the main text. Data are presented as FC over vehicle. Significant (<0.05) p values compared with the vehicle from one-way ANOVA are shown. For (C), (D), and (G), data are displayed as geometric mean ± 95% confidence intervals with technical replicates displayed from three independent experiments. ASPC, adipose stromal and progenitor cell.

    Article Snippet: Human recombinant SAA1 protein , OriGene , Cat#TP310664.

    Techniques: Comparison, Protein-Protein interactions, Expressing, Derivative Assay, Control, Enzyme-linked Immunosorbent Assay, Incubation, DNA Methylation Assay

    (A) Top Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways based on differentially expressed genes from comparisons of SAA1- or LPS-treated vs. control-treated adipose-derived stromal-vascular cells. (B) Network view of the six common SAA1- and LPS-regulated pathways showing shared and treatment-specific genes. (C) Expression scores for SAA1- (left) and LPS-responsive (right) genes following a 6-h incubation with either ligand in stromal-vascular cells from subcutaneous human WAT. Results are displayed on the uniform manifold approximation and projection panel from and violin plots for each indicated cell class. Note that adipocytes and mesothelial cells were removed as these are not present in the stromal-vascular fraction from the subcutaneous depot. (D) Representative immunostaining of epiploic adipose tissue using antibodies directed against markers for Adipo SAA (CES1) and macrophages (CD68). Hoechst33342 was used as the counterstain for nuclei. Scale bar, 100 μm. ASPC, adipose stromal and progenitor cell; NES, normalized enrichment score.

    Journal: Cell metabolism

    Article Title: Cytoarchitectural multi-depot profiling reveals immune-metabolic crosstalk in human colon-associated adipose tissue

    doi: 10.1016/j.cmet.2025.12.008

    Figure Lengend Snippet: (A) Top Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways based on differentially expressed genes from comparisons of SAA1- or LPS-treated vs. control-treated adipose-derived stromal-vascular cells. (B) Network view of the six common SAA1- and LPS-regulated pathways showing shared and treatment-specific genes. (C) Expression scores for SAA1- (left) and LPS-responsive (right) genes following a 6-h incubation with either ligand in stromal-vascular cells from subcutaneous human WAT. Results are displayed on the uniform manifold approximation and projection panel from and violin plots for each indicated cell class. Note that adipocytes and mesothelial cells were removed as these are not present in the stromal-vascular fraction from the subcutaneous depot. (D) Representative immunostaining of epiploic adipose tissue using antibodies directed against markers for Adipo SAA (CES1) and macrophages (CD68). Hoechst33342 was used as the counterstain for nuclei. Scale bar, 100 μm. ASPC, adipose stromal and progenitor cell; NES, normalized enrichment score.

    Article Snippet: Human recombinant SAA1 protein , OriGene , Cat#TP310664.

    Techniques: Control, Derivative Assay, Expressing, Incubation, Immunostaining

    A Circle plot summarizing the maximum number of interactions among individual cell types in metastatic lesions. The thickness of the connecting lines represents the interaction strength. B Comparison of the overall information flow, including the number and strength of interactions, within the inferred networks between PTC and metastatic lesions. C Heatmap displaying the potential outgoing and incoming interaction strength of each cellular cluster in PTC and metastatic lesions. D Heatmap illustrating the relative signaling contribution of each cell group based on the number and strength of interactions, comparing PTC with metastatic lesions. E Differential network centrality analysis based on EMT-like cancer-associated fibroblasts (CAFs), comparing PTC and metastatic lesions. F Bubble heatmap showing the cell-cell communication of selected ligand-receptor pairs between EMT-like CAFs and CD8 + PDCD1 + T cells. Dot size indicates the P -value, while color represents the communication probability. G Multiplex immunohistochemistry (mIHC) validation of the cross-talk between SAA1+ CAFs and T cells via the PPIA-BSG ligand-receptor interaction.

    Journal: NPJ Precision Oncology

    Article Title: Comprehensive single-cell RNA analysis reveals intertumoral microenvironment heterogeneity and hub niche of carcinogenesis in thyroid cancer

    doi: 10.1038/s41698-025-00924-7

    Figure Lengend Snippet: A Circle plot summarizing the maximum number of interactions among individual cell types in metastatic lesions. The thickness of the connecting lines represents the interaction strength. B Comparison of the overall information flow, including the number and strength of interactions, within the inferred networks between PTC and metastatic lesions. C Heatmap displaying the potential outgoing and incoming interaction strength of each cellular cluster in PTC and metastatic lesions. D Heatmap illustrating the relative signaling contribution of each cell group based on the number and strength of interactions, comparing PTC with metastatic lesions. E Differential network centrality analysis based on EMT-like cancer-associated fibroblasts (CAFs), comparing PTC and metastatic lesions. F Bubble heatmap showing the cell-cell communication of selected ligand-receptor pairs between EMT-like CAFs and CD8 + PDCD1 + T cells. Dot size indicates the P -value, while color represents the communication probability. G Multiplex immunohistochemistry (mIHC) validation of the cross-talk between SAA1+ CAFs and T cells via the PPIA-BSG ligand-receptor interaction.

    Article Snippet: We performed multiplex immunofluorescence staining using the following primary antibodies: THBS1 rabbit anti-human antibody (Affinity Biosciences; catalog no. DF6848), CD47 rabbit anti-human antibody (Affinity Biosciences; catalog no. DF6649), CD68 rabbit anti-human antibody (Affinity Biosciences; catalog no. DF7518), APOE rabbit anti-human antibody (Affinity Biosciences; catalog no. AF5178), CD3 rabbit anti-human antibody (Affinity Biosciences; catalog no. DF6848), THBS1 rabbit anti-human antibody (Affinity Biosciences; catalog no. DF6594), BSG rabbit anti-human antibody (Affinity Biosciences; catalog no. AF5221), COL3A1 rabbit anti-human antibody (Affinity Biosciences; catalog no. AF5457), PPIA rabbit anti-human antibody (Proteintech Group; catalog no. 10720-1-AP), and SAA1 rabbit anti-human antibody (Proteintech Group; catalog no. 16721-1-AP).

    Techniques: Comparison, Multiplex Assay, Immunohistochemistry, Biomarker Discovery

    TGFβ1 signaling in primary CRC and LM-CRC CAFs induces expression of IL-6 (A) Schematic overview of workflow for CAF isolation and TGFβ1 pathway-targeted qPCR array. (B) RNA expression of TGFβ1 target genes in two primary CRC CAFs (CAF1 and CAF2) and one LM-CRC CAF. qPCR values have been log transformed. (C) Numerical values depicting the seven TGFβ1 target genes that showed consistent upregulation. (D) Fold change RNA expression of these seven TGFβ1 target genes (yellow symbols). (E) IL6 RNA expression in primary CRC CAFs (CAF4 and CAF5) and the CCD-18Co colon fibroblast line after stimulation with TGFβ1 or medium control. N = 3 CCD-18Co, CAF4; N = 2 CAF5 independent biological experiments. ∗∗ p ≤ 0.01 determined by paired T test. (F) Protein expression of IL-6 in tissue lysates of normal colon and primary CRC (left panel, N = 50) or normal liver and LM-CRC (right panel, N = 50) as determined by ELISA. ∗∗∗∗ p ≤ 0.0001, ∗ p ≤ 0.05 determined by unpaired T test. (G) IL6 RNA expression in unstimulated normal colon fibroblasts ( N = 8) or primary CRC CAFs ( N = 10). (H) RNA expression of IL6 in the original CMS classified cohort (CMS1: N = 457; CMS2: N = 1183; CMS3: N = 409; CMS4: N = 773). ∗∗∗∗ p ≤ 0.0001 determined by one-way ANOVA with correction for multiple testing (Dunnett’s test).

    Journal: iScience

    Article Title: TGFβ signaling in cancer-associated fibroblasts drives a hepatic gp130-dependent pro-metastatic inflammatory program in colorectal cancer

    doi: 10.1016/j.isci.2025.113696

    Figure Lengend Snippet: TGFβ1 signaling in primary CRC and LM-CRC CAFs induces expression of IL-6 (A) Schematic overview of workflow for CAF isolation and TGFβ1 pathway-targeted qPCR array. (B) RNA expression of TGFβ1 target genes in two primary CRC CAFs (CAF1 and CAF2) and one LM-CRC CAF. qPCR values have been log transformed. (C) Numerical values depicting the seven TGFβ1 target genes that showed consistent upregulation. (D) Fold change RNA expression of these seven TGFβ1 target genes (yellow symbols). (E) IL6 RNA expression in primary CRC CAFs (CAF4 and CAF5) and the CCD-18Co colon fibroblast line after stimulation with TGFβ1 or medium control. N = 3 CCD-18Co, CAF4; N = 2 CAF5 independent biological experiments. ∗∗ p ≤ 0.01 determined by paired T test. (F) Protein expression of IL-6 in tissue lysates of normal colon and primary CRC (left panel, N = 50) or normal liver and LM-CRC (right panel, N = 50) as determined by ELISA. ∗∗∗∗ p ≤ 0.0001, ∗ p ≤ 0.05 determined by unpaired T test. (G) IL6 RNA expression in unstimulated normal colon fibroblasts ( N = 8) or primary CRC CAFs ( N = 10). (H) RNA expression of IL6 in the original CMS classified cohort (CMS1: N = 457; CMS2: N = 1183; CMS3: N = 409; CMS4: N = 773). ∗∗∗∗ p ≤ 0.0001 determined by one-way ANOVA with correction for multiple testing (Dunnett’s test).

    Article Snippet: SAA1 concentrations in patient sera were measured using a commercially available kit (Human SAA1 DuoSet ELISA, R&D Systems) and a decrease of ≥0.3 OD450 value between post and pre-surgery sera was considered significant.

    Techniques: Expressing, Isolation, RNA Expression, Transformation Assay, Control, Enzyme-linked Immunosorbent Assay

    IL-6 signaling in CAFs is partly regulated through autocrine TGFβ1 signaling (A) RNA expression of IL6 in CAFs derived either from the primary tumor (CRC CAF, N = 18) or liver metastasis (LM-CRC CAF, N = 6). ∗∗∗ p ≤ 0.001 determined by unpaired T test. (B) RNA-seq data from GSE46824 dataset showing IL6 RNA expression in an independent cohort of primary CRC CAFs ( N = 14) and LM-CRC CAFs ( N = 11). ∗∗∗ p ≤ 0.001 determined by unpaired T test. (C) IL-6 protein expression in unstimulated primary CRC CAF ( N = 8) and LM-CRC CAF ( N = 6) supernatant determined by ELISA. ∗∗ p ≤ 0.01 determined by unpaired T test. (D and E) IL-6 protein expression in TGFβ1-stimulated (5 ng/mL) primary CRC CAFs ( N = 8) (D) and LM-CRC CAFs ( N = 6) (E). ∗ p ≤ 0.05 determined by unpaired T test. (F) Fold change IL-6 protein expression in supernatant from TGFβ1-stimulated vs. unstimulated primary CRC CAFs ( N = 8) and LM-CRC CAFs ( N = 6). ns, p > 0.05 determined by unpaired T test. (G) Percentage decrease in IL-6 protein expression in supernatant in primary CRC ( N = 5) and LM-CRC ( N = 5) CAFs after inhibition with SB431532 (Alk5 inhibitor). ns, p > 0.05 determined by unpaired T test. (H) RNA-seq data from GSE46824 dataset (2B) showing TGFβ1 RNA expression in an independent cohort of primary CRC CAFs ( N = 14) and LM-CRC CAFs ( N = 11). ∗ p ≤ 0.05 determined by unpaired T test. (I) TGFβ1 protein expression in unstimulated primary CRC CAF ( N = 5) and LM-CRC CAF ( N = 6) supernatant determined by ELISA. ∗ p ≤ 0.05 determined by unpaired T test.

    Journal: iScience

    Article Title: TGFβ signaling in cancer-associated fibroblasts drives a hepatic gp130-dependent pro-metastatic inflammatory program in colorectal cancer

    doi: 10.1016/j.isci.2025.113696

    Figure Lengend Snippet: IL-6 signaling in CAFs is partly regulated through autocrine TGFβ1 signaling (A) RNA expression of IL6 in CAFs derived either from the primary tumor (CRC CAF, N = 18) or liver metastasis (LM-CRC CAF, N = 6). ∗∗∗ p ≤ 0.001 determined by unpaired T test. (B) RNA-seq data from GSE46824 dataset showing IL6 RNA expression in an independent cohort of primary CRC CAFs ( N = 14) and LM-CRC CAFs ( N = 11). ∗∗∗ p ≤ 0.001 determined by unpaired T test. (C) IL-6 protein expression in unstimulated primary CRC CAF ( N = 8) and LM-CRC CAF ( N = 6) supernatant determined by ELISA. ∗∗ p ≤ 0.01 determined by unpaired T test. (D and E) IL-6 protein expression in TGFβ1-stimulated (5 ng/mL) primary CRC CAFs ( N = 8) (D) and LM-CRC CAFs ( N = 6) (E). ∗ p ≤ 0.05 determined by unpaired T test. (F) Fold change IL-6 protein expression in supernatant from TGFβ1-stimulated vs. unstimulated primary CRC CAFs ( N = 8) and LM-CRC CAFs ( N = 6). ns, p > 0.05 determined by unpaired T test. (G) Percentage decrease in IL-6 protein expression in supernatant in primary CRC ( N = 5) and LM-CRC ( N = 5) CAFs after inhibition with SB431532 (Alk5 inhibitor). ns, p > 0.05 determined by unpaired T test. (H) RNA-seq data from GSE46824 dataset (2B) showing TGFβ1 RNA expression in an independent cohort of primary CRC CAFs ( N = 14) and LM-CRC CAFs ( N = 11). ∗ p ≤ 0.05 determined by unpaired T test. (I) TGFβ1 protein expression in unstimulated primary CRC CAF ( N = 5) and LM-CRC CAF ( N = 6) supernatant determined by ELISA. ∗ p ≤ 0.05 determined by unpaired T test.

    Article Snippet: SAA1 concentrations in patient sera were measured using a commercially available kit (Human SAA1 DuoSet ELISA, R&D Systems) and a decrease of ≥0.3 OD450 value between post and pre-surgery sera was considered significant.

    Techniques: RNA Expression, Derivative Assay, RNA Sequencing, Expressing, Enzyme-linked Immunosorbent Assay, Inhibition

    TGFβ isoforms are elevated in CMS4 subtype CRC and are capable of inducing IL-6 expression (A–C) RNA expression of the three TGFβ isoforms in the original CMS cohort (CMS1: N = 457; CMS2: N = 1183; CMS3: N = 409; CMS4: N = 773). ∗∗∗∗ p ≤ 0.0001 determined by one-way ANOVA with correction for multiple testing (Dunnett’s test). (D) Protein expression of TGFβ isoforms in the supernatant of primary CRC and LM-CRC CAFs 48 h after the start of serum starvation as determined by ELISA. (E and F) Expression of IL-6 in supernatant of primary CRC CAFs ( N = 7) (E) or LM-CRC CAFs ( N = 6) (F) 48 h after start stimulation with either TGFβ2 or TGFβ3. ∗ p ≤ 0.05 determined by paired T test.

    Journal: iScience

    Article Title: TGFβ signaling in cancer-associated fibroblasts drives a hepatic gp130-dependent pro-metastatic inflammatory program in colorectal cancer

    doi: 10.1016/j.isci.2025.113696

    Figure Lengend Snippet: TGFβ isoforms are elevated in CMS4 subtype CRC and are capable of inducing IL-6 expression (A–C) RNA expression of the three TGFβ isoforms in the original CMS cohort (CMS1: N = 457; CMS2: N = 1183; CMS3: N = 409; CMS4: N = 773). ∗∗∗∗ p ≤ 0.0001 determined by one-way ANOVA with correction for multiple testing (Dunnett’s test). (D) Protein expression of TGFβ isoforms in the supernatant of primary CRC and LM-CRC CAFs 48 h after the start of serum starvation as determined by ELISA. (E and F) Expression of IL-6 in supernatant of primary CRC CAFs ( N = 7) (E) or LM-CRC CAFs ( N = 6) (F) 48 h after start stimulation with either TGFβ2 or TGFβ3. ∗ p ≤ 0.05 determined by paired T test.

    Article Snippet: SAA1 concentrations in patient sera were measured using a commercially available kit (Human SAA1 DuoSet ELISA, R&D Systems) and a decrease of ≥0.3 OD450 value between post and pre-surgery sera was considered significant.

    Techniques: Expressing, RNA Expression, Enzyme-linked Immunosorbent Assay

    TGFβ-mediated IL-6 production by CAFs induces the expression of neutrophil chemoattractants SAA1 and CXCL5 in hepatocytes (A) Schematic overview of ‘CAF priming of Huh-7 hepatocytes’, referring to Huh-7 cells that are exposed to TGFβ1-stimulated CRC CAF CM. (B) Western blot for pSTAT3 and total STAT3 in wildtype Huh-7 cells that were stimulated with CAF CM or TGFβ1 CAF CM from 3 different CRC CAF lines. (C) RNA expression of SAA1 and CXCL5 in wildtype Huh-7 cells stimulated with DMEM 0% FCS (Control), IL-6 (50 ng/mL), CAF CM, or TGFβ1 CAF CM. N = 2 or N = 3 for the Control group, due to the very low SAA1 expression; for the other conditions, N = 3.∗∗∗ p ≤ 0.001, ∗∗ p ≤ 0.01, ∗ p ≤ 0.05 determined by one-way ANOVA with correction for multiple testing (Dunnett’s test). (D and E) RNA expression of SAA1 and CXCL5 in wildtype Huh-7 cells after CAF priming with blockade of specific components of the IL-6 signaling pathway. Siltuximab (anti-IL-6, 2 μg/mL), tocilizumab (anti-IL6R, 8 μg/mL), α-gp130 (anti-gp130, 8 μg/mL), tofacitinib (anti-JAK1/3, 5 μM), or human IgG isotype control (Bio X Cell; 2 μg/mL) were added to Huh-7 cells along with TGFβ1-stimulated CAF CM for 15 min. Subsequently, these different stimulations were applied to Huh-7 cells for 10 min. N = 1 for all different conditions. ∗∗∗∗ p ≤ 0.0001, ∗∗∗ p ≤ 0.001 determined by one-way ANOVA with correction for multiple testing (Dunnett’s test).

    Journal: iScience

    Article Title: TGFβ signaling in cancer-associated fibroblasts drives a hepatic gp130-dependent pro-metastatic inflammatory program in colorectal cancer

    doi: 10.1016/j.isci.2025.113696

    Figure Lengend Snippet: TGFβ-mediated IL-6 production by CAFs induces the expression of neutrophil chemoattractants SAA1 and CXCL5 in hepatocytes (A) Schematic overview of ‘CAF priming of Huh-7 hepatocytes’, referring to Huh-7 cells that are exposed to TGFβ1-stimulated CRC CAF CM. (B) Western blot for pSTAT3 and total STAT3 in wildtype Huh-7 cells that were stimulated with CAF CM or TGFβ1 CAF CM from 3 different CRC CAF lines. (C) RNA expression of SAA1 and CXCL5 in wildtype Huh-7 cells stimulated with DMEM 0% FCS (Control), IL-6 (50 ng/mL), CAF CM, or TGFβ1 CAF CM. N = 2 or N = 3 for the Control group, due to the very low SAA1 expression; for the other conditions, N = 3.∗∗∗ p ≤ 0.001, ∗∗ p ≤ 0.01, ∗ p ≤ 0.05 determined by one-way ANOVA with correction for multiple testing (Dunnett’s test). (D and E) RNA expression of SAA1 and CXCL5 in wildtype Huh-7 cells after CAF priming with blockade of specific components of the IL-6 signaling pathway. Siltuximab (anti-IL-6, 2 μg/mL), tocilizumab (anti-IL6R, 8 μg/mL), α-gp130 (anti-gp130, 8 μg/mL), tofacitinib (anti-JAK1/3, 5 μM), or human IgG isotype control (Bio X Cell; 2 μg/mL) were added to Huh-7 cells along with TGFβ1-stimulated CAF CM for 15 min. Subsequently, these different stimulations were applied to Huh-7 cells for 10 min. N = 1 for all different conditions. ∗∗∗∗ p ≤ 0.0001, ∗∗∗ p ≤ 0.001 determined by one-way ANOVA with correction for multiple testing (Dunnett’s test).

    Article Snippet: SAA1 concentrations in patient sera were measured using a commercially available kit (Human SAA1 DuoSet ELISA, R&D Systems) and a decrease of ≥0.3 OD450 value between post and pre-surgery sera was considered significant.

    Techniques: Expressing, Western Blot, RNA Expression, Control

    The induction of neutrophil chemoattractants in hepatocytes is fully gp130-dependent (A) Western blot for pSTAT3 and total STAT3 in CAF CM-primed Huh-7 cells in which gp-130 signaling is blocked using α-gp130 antibody. α-gp130, anti-gp130. β-actin is used as a loading control. (B) Western blot for pSTAT3 and total STAT3 in vector control, gp130 KO , or gp130 KO rescued Huh-7 cells (gp130 KO+Rescue ) after stimulation with DMEM 0% (Control) or TGFβ1 CAF CM. (C) RNA expression of SAA1 in gp130 KO and gp130 KO+Rescue Huh-7 cells after CAF priming ( N = 3 independent biological experiments). ∗∗ p ≤ 0.01 determined by unpaired T test. (D) IHC of pSTAT3 in Huh-7 cells harboring a vector control, gp130 KO , or gp130 KO+Rescue after stimulation with DMEM 0% or after CAF priming. Scale bar, 50 μm.

    Journal: iScience

    Article Title: TGFβ signaling in cancer-associated fibroblasts drives a hepatic gp130-dependent pro-metastatic inflammatory program in colorectal cancer

    doi: 10.1016/j.isci.2025.113696

    Figure Lengend Snippet: The induction of neutrophil chemoattractants in hepatocytes is fully gp130-dependent (A) Western blot for pSTAT3 and total STAT3 in CAF CM-primed Huh-7 cells in which gp-130 signaling is blocked using α-gp130 antibody. α-gp130, anti-gp130. β-actin is used as a loading control. (B) Western blot for pSTAT3 and total STAT3 in vector control, gp130 KO , or gp130 KO rescued Huh-7 cells (gp130 KO+Rescue ) after stimulation with DMEM 0% (Control) or TGFβ1 CAF CM. (C) RNA expression of SAA1 in gp130 KO and gp130 KO+Rescue Huh-7 cells after CAF priming ( N = 3 independent biological experiments). ∗∗ p ≤ 0.01 determined by unpaired T test. (D) IHC of pSTAT3 in Huh-7 cells harboring a vector control, gp130 KO , or gp130 KO+Rescue after stimulation with DMEM 0% or after CAF priming. Scale bar, 50 μm.

    Article Snippet: SAA1 concentrations in patient sera were measured using a commercially available kit (Human SAA1 DuoSet ELISA, R&D Systems) and a decrease of ≥0.3 OD450 value between post and pre-surgery sera was considered significant.

    Techniques: Western Blot, Control, Plasmid Preparation, RNA Expression

    The IL-6 family of cytokine-JAK-STAT signaling axis is active in CMS4 CRC in vivo (A) Schematic overview of the KPN GEMM organoid experiment. (B) Gene Set Enrichment analysis shows the Enrichment Score (ES) for the IL6-JAK-STAT signaling hallmark in KPN tumor tissue ( N = 3) and wildtype normal colon ( N = 3). (C) Normalized counts of IL6, IL11, and LIF in KPN tumor tissue (KPN) and normal colon tissue (WT). ∗∗∗∗ p ≤ 0.0001, ∗∗ p ≤ 0.01 determined by unpaired T test. (D) Quantification of automated scoring of Ly6G staining in pre-metastatic livers of KPN transplanted mice ( N = 4) and WT livers ( N = 5). (E) Representative IHC of pSTAT3, Ly6G, and GFP in pre-metastatic and metastatic livers in the KPN GEMM. Scale bar, 50 μm. (F) Waterfall plot of the difference in serum SAA1 OD450 value before and after surgery in 16 patients with primary CRC without liver metastasis.

    Journal: iScience

    Article Title: TGFβ signaling in cancer-associated fibroblasts drives a hepatic gp130-dependent pro-metastatic inflammatory program in colorectal cancer

    doi: 10.1016/j.isci.2025.113696

    Figure Lengend Snippet: The IL-6 family of cytokine-JAK-STAT signaling axis is active in CMS4 CRC in vivo (A) Schematic overview of the KPN GEMM organoid experiment. (B) Gene Set Enrichment analysis shows the Enrichment Score (ES) for the IL6-JAK-STAT signaling hallmark in KPN tumor tissue ( N = 3) and wildtype normal colon ( N = 3). (C) Normalized counts of IL6, IL11, and LIF in KPN tumor tissue (KPN) and normal colon tissue (WT). ∗∗∗∗ p ≤ 0.0001, ∗∗ p ≤ 0.01 determined by unpaired T test. (D) Quantification of automated scoring of Ly6G staining in pre-metastatic livers of KPN transplanted mice ( N = 4) and WT livers ( N = 5). (E) Representative IHC of pSTAT3, Ly6G, and GFP in pre-metastatic and metastatic livers in the KPN GEMM. Scale bar, 50 μm. (F) Waterfall plot of the difference in serum SAA1 OD450 value before and after surgery in 16 patients with primary CRC without liver metastasis.

    Article Snippet: SAA1 concentrations in patient sera were measured using a commercially available kit (Human SAA1 DuoSet ELISA, R&D Systems) and a decrease of ≥0.3 OD450 value between post and pre-surgery sera was considered significant.

    Techniques: In Vivo, Staining